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Molecular Mechanisms underlying Inhibition of Microphthalmia-associated Transcription Fac-
tor (MITF) Expression by Transcription Factor GLI2 and Transforming Growth Factor-β
M Pierrat, V Marsaud, A Mauviel and D Javelaud Institut Curie, Orsay, France
The melanocyte-specific transcription factor M-MITF is involved in numerous aspects of melanoblast
lineage biology including pigmentation, survival, and migration. It plays complex roles at all stages
of melanoma progression and metastasis. We established previously that GLI2, a Kruppel-like tran-
scription factor that acts downstream of Hedgehog signaling, is a direct transcriptional target of the
TGF-β/SMAD pathway and contributes to melanoma progression, exerting antagonistic activities
against M-MITF to control melanoma cell invasiveness. Herein, we dissected the molecular mech-
anisms underlying both TGF-β and GLI2-driven M-MITF gene repression. Using transient cell trans-
fection experiments with M-MITF promoter constructs, chromatin immunoprecipitation, site-directed
mutagenesis, and electrophoretic mobility shift assays, we identified a GLI2 binding site within the
-334/-296 region of the M-MITF promoter, critical for GLI2-driven transcriptional repression. This
region is, however, not needed for inhibition of M-MITF promoter activity by TGF-β. We determined
that TGF-β rapidly repressed protein kinase A activity, thus reducing both phospho-cAMP-response
element-binding protein (CREB) levels and CREB-dependent transcription of the M-MITF promoter.
Increased GLI2 binding to its cognate cis-element, associated with reduced CREB-dependent tran-
scription, allowed maximal inhibition of the M-MITF promoter via two distinct mechanisms.
705 
Lack of PTEN overcomes senescence barrier and promotes melanoma metastasis on a NRAS
background
A Conde Perez,1 C Longvert,1 G Gros,1 I Puig,1 F Beermann,2 L van Kempen3 and L Larue1 1
Institut Curie, Orsay, France, 2 EPFL, Lausanne, Switzerland and 3 Mc Gill University,
Montreal, QC, Canada
Melanocyte transformation is a combinatorial multi-step, multi-etiological event that results in one
of the most lethal types of skin cancer, melanoma, with the average 5 year survival prognosis of
patients with metastatic melanoma less than 5%. Recent evidence has solidified the involvement
of several signaling pathways with altered functions in melanoma, MAPK (NRAS and BRAF) and
most notably PI3K (PTEN). Although BRAF and NRAS have been implicated in the proliferation sta-
tus, PTEN`s exact role during melanoma initiation and progression remains uncertain. We aim to
evaluate PTEN`s role in melanomagenesis and assert the possible cross-talk between both pathways,
notably through NRAS and PTEN, in initiation/progression. Two human melanoma libraries were
screened for NRAS and BRAF alterations, with concomitant loss of PTEN. Interestingly, it appears
that both activation of NRAS with simultaneous loss of PTEN coexist, suggesting non-redundant
functions. To further assess any functional cooperative effect, we generated mice displaying an active
form of NRAS while lacking PTEN using the Cre-Lox system, with directed expression to the
melanocyte lineage. Mice with both genetic aberrations had a dramatic increase in melanoma for-
mation, and lung metastasis, with decreased latency period. These results suggest that PTEN loss
and hyperactivation of NRAS cooperate, and that PTEN loss enhances melanoma initiation by bypass-
ing the senescence barrier. Altogether, lack of PTEN with activated NRAS promotes melanoma ini-
tiation and progression.
706
The role of p53 tumor suppressor in melanoma resistance to BRAF inhibitors
G Spallone,1 V Pinetti,1 E Botti,1 M Barysch,2 B Marinari,1 F Moretti,1 M Restelli,3 L Guerrini,3
R Dummer2 and A Costanzo1 1 Dermatology, University of Rome “Tor Vergata”, Rome, Italy, 2
Dermatology, University of Zurich, Zurich, Switzerland and 3 Biomolecular Sciences,
University of Milan, Milan, Italy
Melanoma is an aggressive malignancy whose incidence is increasing very rapidly worldwide. In
melanoma cells, the MAP Kinase signaling pathway is often activated by mutations in BRAF or NRAS.
In particular, BRAF is mutated in about 40% of cutaneous MM. The BRAF inhibitor Vemurafenib is
now the first line treatment for patients with metastatic melanoma with a V600E BRAF mutation.
However the occurence of secondary resistance hampers the efficacy of this drug after 6 to 8 months
of treatment. Mechanisms of resistance are the object of an intense research activity. Resistance to
BRAFi can involve re-activation of the MAP kinase pathwayì by post-translational modifications of
BRAF, by activation of NRAS upstream of BRAF or MEK, downstream or BRAF. Additional pathways
including those activated by IGFR, PDGFR, cKIT or the PI3K pathway can also account for resist-
ance. However, little is known about the role of p53 tumor suppressor gene family in melanoma
resistance to BRAFi. P53 is rarely mutated in melanoma, but is inactivated by conformational change
and is unable to activate cell cycle arrest and apoptosis. We have explored the role of p53 in this
context using cell lines from naïve patients and from patients who developed resistance to BRAFi
and found that p53 displays a counter-intuitive role as a tumor promoter in BRAFi resistant cells.
Melanoma cells with acquired resistance to BRAF inhibitors re-activate p53 transcriptional activity
to promote synthesis of Kit ligand (KITLG), MSH1, activinA and other mediators of invasion and
resistance to BRAFi. These soluble factors act in an autocrine and paracrine way to promote resist-
ance to BRAFi and proliferation. Interestingly, the mdm2 inhibitor Nutlin-3 can efficiently kill BRAFi
resistant cells reacquiring p53 transcriptional activity.
707 
Hgf-Cdk4(R24C) mouse melanomas resist T-cell therapy targeting a melanocytic antigen
through inflammation-induced reversible dedifferentiation
J Landsberg, J Kohlmeyer, M Renn, T Bald and T Tueting Dermatology, University Hospital Bonn,
Bonn, Germany
Adoptive cell therapies (ACT) with CTL targeting melanocytic antigens can achieve remissions in
metastatic melanoma patients, but tumors frequently relapse. To investigate why tumors relapse,
we established an effective ACT protocol in the genetically engineered Hgf-Cdk4 mouse melanoma
model that faithfully recapitulates tumor regression, remission and relapse as seen in patients. Car-
cinogen-exposed Hgf-Cdk4 mice bearing palpable melanomas in the skin received an adoptive
transfer of naïve gp100-specific pmel-1 TCRtg T cells that were activated in vivo with Ad-gp100 fol-
lowed by adjuvant administration of CpG and pI:C. This caused melanoma regression and remis-
sion in the majority of mice. Histopathologic analyses of melanomas that relapsed after several
months revealed focal absence of gp100 expression in amelanotic tumor areas associated with
increased immune cell infiltration. Experiments with a transplantable Hgf-Cdk4 melanoma cell line,
that recapitulated tumor regression, remission and relapse, confirmed the development of acquired
resistance to gp100-specific T cell therapy associated with partial loss of target antigen expression
in an inflammatory microenvironment. Hgf-Cdk4 melanoma cells from relapsed tumors showed a
dedifferentiated phenotype with a strongly reduced ability to stimulate pmel-1 T-cells in vitro. Unex-
pectedly, this dedifferentiated phenotype was reversed upon transplantation in vivo and could again
be induced by adoptively transferred T-cells. Our results demonstrate that immunoselection of tumor
cell variants with persistent genetic aberrations, as predicted by the immunoediting theory, is unex-
pectedly not a prerequisite for melanoma cells to acquire resistance to ACT targeting melanocytic
lineage antigens. Instead, we found that the phenotypic plasticity of melanoma cells in an inflam-
matory microenvironment allowed them to escape T-cell recognition and destruction.
708 
Transient CD271+ve Drug Tolerant Stem Like Melanoma Cells Are Inherently Resistant Towards
BRAF And MEK Inhibition
DR Menon,1 S Das,3 B Rinner,2 K Heike,2 E Bonyadirad,1 G Hoefler3 and H Schaider1 1
Dermatology, Medical university of Graz, Graz, Austria, 2 ZMF, Medical university of Graz,
Graz, Austria and 3 Pathology, Medical university of Graz, Graz, Austria
Melanomas along with many other cancer types harbor BRAF mutations which constitutively acti-
vate the MAPK-ERK1/2 pathway. PLX4032, a BRAF inhibitor, which initially shows an excellent
response in advanced melanoma, gives rise to acquired resistance in most patients. Here, we observed
that long time exposure of PLX4032 in BRAF mutant melanoma cells led to the emergence of a
CD271 high penetrance positive drug tolerant stem cell like population (DTSC). DTSCs exert high
levels of ERK and AKT phosphorylation when compared to the parent cell line with extended dou-
bling times. These properties were drug induced and not dependent on a preexisting population, as
the removal of the drug led to the formation of the parent population which was again sensitive to
the BRAF inhibitor. TGF-beta1 when combined with BRAF or MEK inhibitors drastically reduced or
even completely abrogated the formation of DTSCs, which we identified to be mediated through
down regulation of AKT and STAT3 Tyr 705 signaling. Our studies suggest that TGF-beta1, which is
an important growth factor in the tumor microenvironment, enhances the effect of BRAF and MEK
inhibitors thereby considerably reducing the formation of DTSCs, which play a crucial role in acquired
drug resistance and the survival of cancer cells during drug exposure.
709
Nucleus accumbens associated 1 contributes to cortactin deacetylation and augments the
migration of melanoma cells
K Tsunoda,1 K Takahashi,1 F Maeda,1 Y Ishikawa,1 H Oikawa,3 T Masuda,3 C Maesawa2 and
T Akasaka1 1 Dermatology, Iwate Medical University, Morioka, Japan, 2 Tumor Biology,
Division of Bioscience, Center for Advanced Medical Science, Iwate Medical University,
Morioka, Japan and 3 Pathology, Iwate Medical University, Morioka, Japan
We investigated the prognostic significance and post-transcriptional acetylation-modification of cor-
tactin (CTTN) via the NACC1-HDAC6 deacetylation system in primary melanomas and melanoma
cell lines. Overexpression of CTTN protein was observed in 56 (73%) of 77 stage I-IV melanomas,
and was significantly correlated with tumor thickness, lymph node metastasis, distant metastasis,
and disease outcome. The patients whose tumors exhibited CTTN overexpression had a poorer out-
come than patients without this feature (P=0.028, log-rank test). NACC1 and CTTN proteins, but
not HDAC6, were overexpressed in 4 melanoma cell lines in comparison with a primary culture of
normal human epidermal melanocytes. Knockdown of both NACC1 and HDAC6 markedly down-
regulated the migration activity of all melanoma cell lines (P<0.05), and induced a gain of CTTN
protein acetylation status. Confocal microscopy showed that hyperacetylation of CTTN modulated
by depletion of both NACC1 and HDAC6 induced disappearance of CTTN protein at the leading
edge of migrating cells, resulting in stabilization of the focal adhesion structure and development
of actin stress fibers. These data suggest that the acetylation status of CTTN modulated by the NACC1-
HDAC6 deacetylation system induces acceleration of melanoma cell migration activity via an actin-
dependent cellular process, possibly contributing to aggressive behavior (invasion/metastasis) of the
melanoma cells.
S124 Journal of Investigative Dermatology (2012), Volume 132
ESDR12_Abstracts-3  7/20/12  1:26 PM  Page S124
Pigmentation and Melanoma | ABSTRACTS
710
Deficiency in IL-23, but not IL-12, promotes the development of melanocytic tumors with
regional lymph node involvement in C3H/HeN mice
T Nasti, T Jaleel and L Timares Dermatology, University of Alabama School of Medicine,
Birmingham, AL
Genetic and environmental factors act in concert to deregulate melanocytic stem cells ultimately
leading to their transformation and progression into metastatic melanoma. Treatment of C3H/HeN
mice with dimethylbenz(a)anthracene (DMBA) followed by TPA induces the formation of dysplas-
tic pigmented lesions, but not melanoma. Because IL-12 and IL-23 have been shown to play a crit-
ical role in other types of tumors, their role on the formation of pigmented lesions and their pro-
gression to melanoma was investigated using C3H/HeN mice deficient in IL-12 (p35-/-), IL-23 (p19-/-),
or both IL-12/23 (p40-/-). Panels of mice were treated with DMBA followed by twice weekly doses
of TPA. IL-23 deficiency was found to promote the initiation of pigmented lesions by 50% (p<0.001)
and their radial growth by 100% (p<0.05) compared to wild-type (WT) mice. In contrast, there
were fewer pigmented lesions in p35-/- and WT mice than p40-/- mice. Mouse melanocytes from
WT mice were also found to upregulate IL-23R expression in response to IL-23 but not IL-12, pro-
viding evidence that IL-23 can act directly on melanocytes. Mice subjected to the DMBA/TPA pro-
tocol were found to have nests of melanocytes in their draining lymph nodes when examined his-
tologically. Eighty percent of the LNs obtained from IL-23 KO mice were able to generate melanocytic
cultures from their lymph nodes. In contrast, only 33% of the lymph nodes from IL-12 KO mice
were able to do so. Our findings suggest a novel role for IL-23 in suppressing development of pig-
mented nevi and migration of melanocytic cells to regional lymph nodes.
712
Simultaneous TaqMan® Q-PCR quantitation of hundreds of cancer-related genes in melanoma
cell lines using the OpenArray® technology
D Javelaud,1 D Dewolf,2 E Grigorenko3 and A Mauviel1 1 Institut Curie, Orsay, France, 2 LIfe
Technologies, Saint-Aubin, France and 3 LIfe Technologies, Beverly, MA
We used the TaqMan® OpenArray® technology to simultaneously quantify the expression levels of
approx. 650 distinct genes involved in cancer development in 1205Lu cells, a highly invasive human
melanoma cell line bearing the BRAFV600E mutation. We previously demonstrated that the tran-
scription factor GLI2 is involved in the invasive behavior of melanoma cells, a trait that largely
depends upon TGF-β signaling. We also determined the portion of gene signature regulated by
TGF-β that is controlled by GLI2 in 1205lu melanoma cells treated or not with TGF-β, in the absence
or presence of shRNA-mediated GLI2 knockdown. Following reverse transcription and a pre-ampli-
fication step of only 1 μg of total RNA, simultaneous quantitative PCR with the TaqMan technology
was run onto a QuantStudio™ 12K Flex Real-Time PCR System. 590/650 genes were expressed,
among which approximately 261 were modulated by TGF-β after either a 4- or 24h treatment.
140/261 genes were induced and 120/261 repressed by TGF-β. A number of these genes have been
implicated in the modulation of angiogenesis or invasion. Interestingly, we observed that GLI2 knock-
down altered TGF-β responses in melanoma cells. Specifically, induction by TGF-β of 87/140
genes did not occur in 1205lu cells after GLI2 knockdown compared to controls. Furthermore,
56/120 genes were repressed when GLI2 expression was abolished. Finally, 70/590 genes were
expressed differentially in GLI2 knockdown 1205lu cells vs. controls and represent a subset of genes
essentially involved in cell proliferation and movement. 37/70 genes exhibited increased expres-
sion in GLI2 knockdown cells, indicating a transcriptional repressor function of GLI2 on those genes.
This study identifies new targets of both GLI2 and the TGF-β pathway in melanoma cells, and high-
lights the critical role played by GLI2 to regulate gene expression downstream of TGF-β signaling.
714 
Wnt/β-catenin signaling in melanoma: learning from low passage cell lines isolated from pri-
mary human melanoma
B Bellei,1 D Kovacs,1 A Ferrari,2 V Silipo,2 P Buccini,2 E Migliano,4 S Bucher,4 L Muscardin,3
P Donati3 and C Catricalà2 1 Laboratory of Cutaneous Physiopatology, San Gallicano
Dermatological Institute, IRCCS, Rome, Italy, 2 Melanoma Unit, San Gallicano Dermatological
Institute, IRCCS, Rome, Italy, 3 Dermatopathology Unit, San Gallicano Dermatological
Institute, IRCCS, Rome, Italy and 4 Chirurgia Plastica Ricostruttiva, San Gallicano
Dermatological Institute, IRCCS, Rome, Italy
Dysregulation or mutation of Wnt/β-catenin pathway is implicated in both neotransformation and
malignant progression of various cancer types. However, contradictory results concerning the role
of β-catenin in human melanoma address an open question on the oncogenic nature and prognostic
value of β-catenin in melanoma. Recently, change in Wnt signaling regulation has been linked to
melanoma cells switching between highly proliferative/non-invasive phenotype and invasive/metasta-
tic phenotype. We have employed a novel panel of cell lines isolated from primary melanoma
specimens, at initial passages, to investigate phenotype (proliferative and invasive) differences in the
levels and activity of Wnt/β-catenin signaling. This in vitro cell system revealed intra-tumoral het-
erogeneity that comprises, in some cases, two well distinct subpopulations of cells presenting dif-
ferent levels of β-catenin activation and distribution. Increased β-catenin cytoplasmic and mem-
brane bound distribution inversely correlates with cell proliferation rate. Moreover, low
β-catenin-dependent transcription activity corresponds to the epithelial-mesenchymal transition
compatible with invasive phenotype: low level of differentiation markers, loss of E-cadherin and
simultaneous activation of N-cadherin expression. According with genes expression profile pro-
posed for the melanoma invasive phenotype we also demonstrated higher level of VEGF, MMP3 and
MMP9, and Wnt5a. Interestingly, subpopulations of cells possessing stem cell-like properties dis-
play attenuated Wnt/β-catenin signaling activation compared to the parental cell line. Our study
also confirmed that mutations in exon 3 of the β-catenin gene are rare events in primary melanoma.
713
DNA methylation in melanoma phenotype switching
PF Cheng, DS Widmer, B Belloni, OM Eichhoff, M Raaijmakers, KS Hoek, R Dummer and
MP Levesque Dermatology, University Hospital Zurich, Zurich, Switzerland
Melanoma is the most aggressive skin cancer worldwide. Although melanoma is curable when
detected in early stages of progression, patients diagnosed with late stage and metastatic melanomas
have very poor survival. The difficulty in treating late stage and metastatic melanoma patients has
been attributed to the heterogeneity of melanoma. However the molecular mechanisms of estab-
lishing heterogeneity are currently unknown. To investigate the role of DNA methylation on melanoma
heterogeneity we performed DNA methylation profiling of 10 melanoma cell cultures established
from 10 patient melanoma biopsies by methylated DNA immunoprecipitation (MeDIP) microarray
analysis. The DNA methylation profile of the 10 melanoma cell cultures could be clustered into
two distinct cohorts. Analysis of the two profiles revealed enrichment for genes involved in neural
crest differentiation, such as SOX9, FOXD3, FGF2, FZD3, and PDGFRa. These results suggest that
DNA methylation might be a mechanism which regulates neural crest differentiation factors in
melanoma. Reexpression of these neural crest differentiation factors in the invasive phenotype sug-
gests that the melanoma cells return to a dedifferentiated state for invasion.
711
Identification of miR-145 as a key regulator of the pigmentary process
P Dynoodt,1 P Mestdagh,2 G Van Peer,2 J Vandesompele,2 K Goossens,3 R Speeckaert,1 J Lambert1
and M Van Gele1 1 Dermatology, Ghent University Hospital, Ghent, Belgium, 2 Center for
Medical Genetics, Ghent University Hospital, Ghent, Belgium and 3 Department of Nutrition,
Genetics and Ethology, Ghent University, Merelbeke, Belgium
The current hyperpigmentation treatments are often associated with a lack of efficacy and major
side-effects. We hypothesized that microRNA (miRNA) based treatments may offer an attractive alter-
native by specifically targeting key genes in melanogenesis. The aim of this study was to identify
miRNAs interfering with the pigmentary process and to assess their functional role. MiRNA profil-
ing was performed on mouse melanocytes (melan-a) after 3 consecutive treatments involving forskolin
and ssUV irradiation. The differential expression of miRNAs was determined by a multiplex qPCR
platform utilizing RT stem-loop primers and Taqman probes. Sixteen miRNAs were identified as dif-
ferentially expressed in treated melan-a cells versus untreated cells. Remarkably, a 15-fold down-
regulation of miR-145 was detected. We decided to investigate its effect on genes involved in melano-
genesis or melanosome transport by use of functional assays. Modulation of miR-145 expression in
melan-a cells and human primary melanocytes resulted in a significant down- or upregulation of
major pigmentation genes or genes involved in the transport of melanosomes to the cell periphery.
Moreover, target prediction database analysis combined with luciferase reporter assays showed
direct targeting of myosin Va by miR-145. Transient overexpression of miR-145 in human melanocytes
resulted in a reduced MYO5A protein level followed by a perinuclear accumulation of melanosomes
and a clearly visible depigmentation effect in vitro. In conclusion, this study established for the first
time a miRNA signature associated with forskolin and ssUV treatment. The significant down- or
upregulation of myosin Va together with other important pigmentation genes, after modulation of
miR-145 expression, suggests a key role for miR-145 in the regulation of melanogenesis. Therefore,
miR-145 is a potential therapeutic target in the treatment of skin pigmentation disorders.
715
Renewed interest about fibroblasts in dermal hyperpigmentary disorders
H Ando,1 S Inoue,1 K Ohtsubo,1 K Akiyama,2 M Ito,3 M Yagi4 and M Ichihashi5 1 Department of
Applied Chemistry and Biotechnology, Okayama University of Science, Okayama, Japan, 2
Hanaichi Ultrastructure Research Institute Co., Okazaki, Japan, 3 Department of
Dermatology, Niigata University, Niigata, Japan, 4 Rosette Co., Tokyo, Japan and 5 SAISEI
MIRAI Clinic Kobe, Kobe, Japan
It is known that melanophages, possibly derived from macrophages or histiocytes that ingest
melanosomes, are involved in dermal pigmentation. We recently reported that melanocytes pro-
duce multiple melanosome-containing globules from their dendrites and release them into the extra-
cellular space. Here we propose that melanosome-containing globules phagocytosed by dermal
fibroblasts are also involved in dermal pigmentary disorders. We compared the phagocytotic abil-
ities of keratinocytes and fibroblasts in vitro using isolated individual melanosomes and melanosome-
containing globules, and found that keratinocytes incorporated both of them in large amounts, while
fibroblasts preferred to ingest melanosome-containing globules rather than individual melanosomes.
In addition, degradation of the limiting double membrane structure of melanosome-containing glob-
ules was much more prominent in keratinocytes than in fibroblasts. These results suggest that fibrob-
lasts in vivo may ingest multiple melanosome-containing globules that have dropped down into the
dermis and may keep them for prolonged times in their cytoplasm due to their inactive degradation
capability, which lead to the characteristics of dermal pigment deposition.
www.jidonline.org   S125
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p62: a novel diagnostic and prognostic biomarker of malignant melanoma
R Ellis,1 J Armstrong,1 N Kirkham,2 T Ness,2 S Horswell3 and P Lovat1 1 Dermatological Sciences,
Newcastle University, Newcastle, United Kingdom, 2 Deptartment of Pathology, Royal
Victoria Infirmary, Newcastle, United Kingdom and 3 London Research Institute, London,
United Kingdom
While the prognosis for early stage melanoma is favourable, metastatic disease remains largely
untreatable. Biomarkers to refine risk of disease progression and predict patients that would bene-
fit from stratified treatment are fundamental to developing novel therapies and improving outcomes.
Tumour progression relies on clearance of aggregate prone proteins/damaged organelles via the
ubiquitin-proteosome and autophagy-lysosome systems. The adaptor protein p62 recruits ubiquiti-
nated proteins, which upon lysosomal degradation, aid tumour survival. Since p62 is associated
with defective autophagy and tumour severity, a semi-quantitative immunohistochemical assay
was used to quantify p62 expression in a cohort of naevi and primary cutaneous melanoma sam-
ples to assess its potential as a diagnostic and prognostic biomarker. p62 levels were determined in
a statistically powered retrospective cohort of benign naevi (n=30) and primary melanoma forma-
lin-fixed paraffin-embedded tissue from patients of varied AJCC disease stage (n=119) as well as in
a panel of melanocytic lesions of uncertain malignant potential (n=20). p62 expression was signif-
icantly increased in melanoma compared to naevi (p<0.0001). Univariate analysis revealed a sig-
nificant correlation between p62 expression (mean +ve tumour cells <20%) and decreased disease
free survival (DFS) (hazard ratio 1.99, 95% CI 1.06-3.77, p<0.05), as well as increased mortality.
Combining AJCC disease stage and p62 expression, also highlighted an increased rate of metas-
tases in patients with p62 levels <20% (HR 2.14, 95% CI 1.02-4.47, p<0.05), again associated with
increased mortality. These data demonstrate p62 represents a novel diagnostic and prognostic bio-
marker for melanoma. As a biomarker, p62 expression will impact on the diagnosis of difficult to
define melanocytic lesions and provide prognostic information in melanoma, over and above AJJC
staging, that will aid patient stratification and earlier personalized therapeutic intervention.
717
Regulation of melanoma invasion through PDE4
A Servy,2 F Laugier,2 A Bensussan,1 M Bagot3 and N Dumaz1 1 U976, INSERM, Paris, France, 2
UMR-S-976, Univ Paris Diderot, Paris, France and 3 Dematology Department, AP-HP, Paris,
France
Transformation of melanocytes by oncogenic BRAF inhibits cAMP signaling. We found that the
molecular mechanism of this inhibition involves members of the phosphodiesterase (PDE) super-
family, enzymes that physiologically degrade cAMP. More specifically, using a range of PDE inhibitors,
we identified the PDE4 subgroup as a major suppressor of cAMP signalling in melanoma. The com-
bination of PDE4 inhibitors and α-MSH stimulated CREB protein phosphorylation, indicating that
the cAMP/PKA-signalling pathway in response to α-MSH was restored in these cells. Interestingly,
we found that reactivating the cAMP pathway in BRAF mutated melanoma did not inhibit prolifer-
ation but inhibited invasion and colony formation. This is different from RAS mutated melanoma,
where reactivating the cAMP pathway induced apoptosis. Phosphodiesterase inhibitors induced
only transient CREB phosphorylation and did not induce MITF. The inhibition of invasion seems
therefore independent of MITF and may involve interaction of PDE4 with FAK through the scaffold
protein RACK1. These results have implications for our understanding of melanoma biology and
could also be used for therapy. Targeted inhibition of PDE4 isoforms may indeed serve as a com-
plementary therapeutic approach for the treatment of melanoma harbouring BRAF or RAS mutants.
718
Characterization of stem cells initiating non malignant melanocytic proliferation
R Fontaine,1 C Charbel,1 A Haas,1 A Picard,2 N Kadlub,2 A Coulomb,3 S Aractingi1 and S Guegan1
1 CdR Saint-Antoine, Inserm UMRS 938, UPMC, Paris, France, 2 Department of Plastic
Surgery, Hôpital Trousseau, AP-HP, Paris, France and 3 Department of Pathology, Hôpital
Trousseau, AP-HP, Paris, France
Large congenital melanocytic nevus (CMN) is a benign tumor present at birth resulting from a pro-
liferation of melanocytes in the dermis and/or epidermis, responsible for major socio-aesthetic prob-
lems with a clear risk of melanoma transformation during infancy or adulthood. Ontogeny of this
peculiar self limited proliferation remains poorly known. We addressed the question of whether
some cells act as initiating stem cells in large CMN, with a possible later accumulation of muta-
tions giving rise to melanomas. 10 children with large CMN, 10 children with small-medium CMN
and 5 adults with spreading superficial melanoma (SSM) have been included in the study. Analysis
of stem cell/progenitors lineage markers, malignant melanocytic stem markers and melanocytic
lineage markers expression by immunohistochemistry and flow cytometry was performed. In vivo,
in both dermis and epidermis, Nestin, Oct4, Sox10, MelanA, Ki67+ cell numbers were increased
in large CMN vs small medium CMN, as well as HMB45 and MITF+ cell numbers in the epider-
mis. Comparison between SSM and large CMN revealed a statistically significant difference in the
number of MelanA, Ki67, Nestin, Oct4, MITF+ cells in both epidermis and dermis and significant
difference in the number of HMB45+ cells in the dermis. In all tested CMN, sorted CD31-CD45-
cell suspensions showed a small percentage of stem markers expressing cells (ABCB5, CD271,
CD166, CD133). CMN specimens were xenografted in brown adipose tissue in Rag2-/- mice. Grafted
tissues from large CMN expanded macroscopically (250% growth) but not those from small-medium
CMN. BrdU+ melanocytes displayed within the outgrowth skin tissue the same benign nested archi-
tecture than in the original nevus. In vitro, large CMN cells formed spheres that could be passaged.
CMN spheres were less frequent and compact than human melanoma cell lines spheres. Altogether,
certain subtypes of nevi cells display features of initiating cells and behave differently from those
issued from melanoma in vivo.
719
Use of the antimicrobial peptide LL37 for immunotherapy of melanoma
O Demaria,1 M Singh,2 C Conrad1 and M Gilliet1 1 Immuno-Dermatologie, CHUV, Lausanne,
Switzerland and 2 MD Anderson Cancer institute, Houston, TX
Melanoma is a highly aggressive form of skin cancer. However, the fact that advanced-stage melanoma
is relatively resistant to chemotherapy led to the search of alternative treatments, including
immunotherapy. Melanoma is potentially immunogenic. However, effective antitumor immune
responses are rarely induced spontaneously, due to the fact that the tumor microenvironment lacks
adequate innate immune activation stimuli required to initiate strong anti-tumor T cell immunity.
Plasmacytoid dendritic cells (pDCs) represent a dendritic cell subset specialized in sensing viral
nucleic acids. During viral infection, pDCs accumulate in infected tissues and are activated to pro-
duce large amounts of type 1 interferons (IFN) that is a central event to the initiation of protective
T cell immunity. Our goal is to mimic this pDC-driven anti-viral immune response to achieve effec-
tive anti-tumor immune T cell responses. Melanoma contain pDCs, which however are not acti-
vated to produce type I IFNs. We recently found that the anti-microbial peptide LL37 can induce
IFN production by pDCs by forming a complex with DNA released by dying cells and allowing the
DNA to enter endosomal compartments of pDC and activate TLR9. Because tumors contain dying
cells releasing large amount of DNA and pDCs, but do not express LL37, we hypothesized that
administration of exogenous LL37 into tumors would lead to formation of LL37-DNA complexes
that are capable of activating pDCs causing type I IFN production at the tumor site and initiating
anti-tumor T cell immune responses. Mice bearing established subcutaneous B16-OVA melanoma
tumors were therefore injected intratumorally with LL37. LL37 was found to induce IFN-α expres-
sion in treated tumors. Furthermore LL37 induced expansion of OVA-antigen-specific CD8 T cells
in draining lymph nodes and their infiltration at the tumor site. This process was associated with a
delay in tumor growth. Together these findings suggest that intratumoral LL37 can induce effective
anti-tumor immunity and provide a new promising strategy for the treatment of advanced-stage
melanoma.
720
Metastatic progression of melanoma is driven by Tlr4-dependent inflammatory responses in
the tumor microenvironment
T Bald, J Landsberg, M Renn and T Tueting Dermatology, University Hospital Bonn, Bonn,
Germany
The induction of inflammatory responses in the tumor microenvironment through stimulation of
toll receptors (Tlr) represents a double-edged sword in tumor development. It can activate anti-tumor
immunity but can also contribute to the survival, proliferation and migration of tumor cells. Here
we experimentally investigated how endogenous Tlr4 ligands released in the skin following treat-
ment with the tumor promoter TPA affect melanomagenesis in the genetically engineered Hgf-
Cdk4 mouse model. Two epicutaneous applications of TPA effectively stimulated epidermal hyper-
plasia and immune cell infiltration in the skin of Hgf-Cdk4 mice. Treatment of Hgf-Cdk4 mice with
TPA twice weekly for 25 weeks induced an infiltrative expansion of melanoma cells in the skin and
systemically in draining lymph nodes and lungs. Long-term TPA treatment of carcinogen-exposed
Hgf-Cdk4R24C mice selectively increased the infiltrative and metastatic growth of melanoma cells.
Repetitive epicutaneous applications of TPA also promoted the metastatic spread of serial Hgf-
Cdk4 melanoma transplants in the skin of wild type mice. The pro-metastatic effect of TPA-induced
inflammation on serial melanoma transplants was completely absent in Tlr4-deficient mice. As a
mechanistic explanation, we found that the presence of Tlr4 on recipient mice was required for
efficient TPA-dependent induction of proinflammatory genes and the expansion of Gr1+CD11b+
myeloid-derived suppressor cells that have been shown to promote metastatic dissemination in other
experimental models. Taken together, these results provide experimental evidence that Tlr4-depend-
ent inflammatory responses in the microenvironment of cutaneous melanomas contribute to the
development of metastatic disease.
721
Melanoma cell miRnome analysis using the TaqMan® OpenArray® technology: Modulation
by TGF-β
D Javelaud,1 D Dewolf,2 E Grigorenko3 and A Mauviel1 1 Institut Curie, Orsay, France, 2 Life
Technologies, Saint-Aubin, France and 3 Life Technologies, Beverly, MA
MicroRNAs (miRNAs) are short, non-coding, RNA regulators of gene expression. In addition to reg-
ulating growth, development or differentiation, some miRNAs have also been classified as tumor
suppressors or oncogenes. We used the TaqMan® OpenArray® technology to simultaneously quan-
tify the expression levels of 750 distinct miRNAs in three human melanoma cell lines, all carrying
the BRAFV600E mutation, but exhibiting distinct pigmentation profiles and invasive capacities,
namely SK-Mel-28, 501mel and 1205Lu cells. 1 μg of total RNA was required for each sample analy-
sis. Following reverse transcription and a pre-amplification step, simultaneous quantitative PCR with
the TaqMan® technology was run onto a QuantStudio™ 12K Flex Real-Time PCR System. 410 dis-
tinct miRNAs were detected, among which approximately 200 were expressed in the three cell lines.
Several of them have been implicated in the modulation of melanogenesis, cell-cell adhesion or
proliferation, and in the modulation of the TGF-β, Hedgehog and WNT pathways. Several distinct
miRNAs were exclusively expressed in 501mel cells, others exclusively in SK-Mel-28 and a larger
number exclusively in the more aggressive 1205Lu cell line. Furthermore, 40 miRNA species detected
in 501mel cells were not expressed in SK-Mel-28 cells while 50 miRNAs found in SK-Mel-28 cells
were not present in 501mel cells. In 1205Lu cells, about 30 miRNAs had their expression dramat-
ically elevated by a 24h TGF-β treatment (at least 2-fold) while a similar number of miRNAs had
their expression significantly reduced. Work is in progress to determine the biological implications
of miRNA profiles in melanoma cells regarding their tumorigenic and metastatic capacities.
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Study of CCN3 (Nov) expression in normal skin and vitiligo skin
C Pain,1 L Benzekri,4 K Ezzedine,3 Y Gauthier,3 V Guyonnet-Dupérat,2 A Bibeyran,2 A Taieb3 and
M Cario-Andre2 1 University V segalen, Bordeaux, France, 2 INSERM 1035, Bordeaux, France,
3 dermatology, Universitary Hospital, Bordeaux, France and 4 Dermatology, Ibn Sina
University Hospital, Mohammed V Souissi University, Rabat, Morocco
We have hypothesized that melanocytes disappear in vitiligo because of melanocytorhagy since
they are weakly attached to basal membrane. In the epidermis, attachment of melanocytes to col-
lagen IV is mediated by DDR1, which is under the control of CCN3. DDR1 genetic variants have
been associated with vitiligo in patients of different ethnic origin. In vitro studies have shown that
inhibition of CCN3 induces the detachment of melanocytes. We have decided to study in parallel
the expression of CCN3, DDR1 and collagen IV in lesional and non-lesional skins of vitiligo patients
and the impact of inhibition of CCN3 and DDR1 in melanocytes. Our in vivo study reveals an alter-
ation of CCN3 expression in vitiligo skin since melanocytes present in perilesional skin does not
always express CCN3 and since CCN3 expression in keratinocytes is increased in lesional skin in
most patients. DDR1 expression is decreased in lesional skin of vitiligo in most patients while the
expression of collagen IV was decreased in all patients. The semi-quantitative analysis of the expres-
sion of CCN3, DDR1 and collagen IV in vitiligo patients reveals a relationship between the expres-
sion level of collagen IV and the presence or absence of lymphocytic infiltrate. In vitro inhibition
of CCN3 in melanocytes results in a decrease in their adhesion to collagen IV, whereas inhibition
of DDR1 does not change their adherence and do not induce their detachment in the reconstructed
epidermis. On the contrary, we were able to observe melanocytes detachment in epidermis recon-
structed with melanocytes transduced by shCCN3. In conclusion, the trio CCN3-DDR1-collagen
IV appears to involve in the pathogenesis of vitiligo and in particular its level of expression appears
to correlate with the presence or absence of lymphocytic infiltrate.
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Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant
melanoma cells while negatively regulating their migration activity
Y Ishikawa,1 K Takahashi,1 K Tsunoda,1 F Maeda,1 T Akasaka,1 C Maesawa2 and T Masuda3 1
Dermatology, Iwate Medical University, Morioka, Japan, 2 Tumor Biology, Iwate Medical
University, Morioka, Japan and 3 Pathology, Iwate Medical University, Morioka, Japan
The cylindromatosis gene (CYLD) encodes a deubiquitinase that was initially identified as a tumor
suppressor and has recently been investigated in connection with a variety of normal physiological
processes. In contrast to its cell-proliferative activity, the effect of CYLD protein on cell migration
has been a matter of debate. Here we investigated the effect of CYLD-siRNA on the migration activ-
ity of malignant melanoma cells. Expression of CYLD mRNA/protein was lower in 6 of 8 malignant
melanoma cell lines than in 3 sets of primary-cultured normal human epidermal melanocytes. Knock-
down of CYLD significantly increased the proliferation activities of two melanoma cell lines (p<0.05),
along with BCL3 nuclear translocation followed by CCND1 overexpression. In contrast to the pro-
liferation-related activity, CYLD knockdown significantly decreased the cell migration of all the
melanoma cell lines (n=7, p<0.05), and we demonstrated that the mechanism regulating melanoma
cell migration was activation of RAC1 through the action of CYLD. Our findings provide a new
insight into the role of CYLD-induced RAC1 activation in melanoma cell migration.
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Clinical profile of BRAF mutated patients with primary or metastatic Melanoma
M Saint-Jean,1 G Quéreux,1 J Nguyen,2 L Peuvrel,1 A Khammari,3 A Knol,4 A Vallée,5 M Denis5
and B Dréno1 1 Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France, 2
PIMESP, Saint-Jacques Hospital, Nantes, France, 3 Inserm U892, CIC Biothérapie Inserm 0503,
Nantes, France, 4 Immuno-Dermatology Laboratory, University Hospital Hôtel-Dieu, Nantes,
France and 5 Biochemistry, University Hospital Hôtel-Dieu, Nantes, France
Discovery of activating BRAF mutations has dramatically changed treatment of metastatic melanoma
patients with Vemurafenib. However, the relationship between BRAF mutations and clinical data is
still under question. The aim of our work is to correlate BRAF mutation with clinical characteristics.
All the patients seen in our unit from January 2011 to April 2012 with a melanoma at least stage II
were screened for BRAF status. DNA was extracted from formalin-fixed paraffin-embedded tissues,
using an iPrep instrument (Invitrogen). BRAF codon 600 mutations were assessed by allele-specific
PCR as previously described. If positive, a standard DNA sequencing was performed. BRAF status
was screened for 326 patients. 170 were male and 156 were female with a median age of 61.9
years. Stage of melanoma was II for 91 patients, III for 115 patients and IV for 120 patients. Ten
samples were mucous melanoma. A BRAF V600 mutation was found in 141 cases (43.25%). BRAF-
mutated patients were significantly younger than non-mutated (p<0.001). 78 primary melanoma
were screened with no difference between UV-exposed and non-exposed location. No difference
of frequency of BRAF mutation was noted between the number of invaded lymph nodes and between
the different types of metastasis. Interestingly, for 58 patients, several samples were screened at dif-
ferent time with concordant results for BRAF mutation in 50 cases but discordant expression in 8
patients (13.8%). Our study confirms that younger age is linked with BRAF mutation. Notably, the
discordant results suggest that independent subclones are generated in some patients. In the era of
targeted therapies, assessment of the spectrum and distribution of alterations in molecular targets
among patients with melanoma is still needed.
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Imiquimod augments the expression of B7H1 on CD11b+Gr1+ myeloid derived suppressor
cells (MDSCs) in B16F10 melanoma
T Fujimura, Y Kambayashi and S Aiba Department of Dermatology, Tohoku University,
Graduate School of Medicine, Sendai, Japan
Myeloid derived suppressor cells (MDSC) comprise a heterogeneous population of cells (CD11b+,
Gr-1+), which can be found in tumor-bearing hosts. We previously reported that MDSC from murine
ret melanoma suppress the activity of T cells together with Tregs through B7H1 mediated pathways.
To investigate the MDSC during melanoma treatment, first, we examined the expression of B7H1
on MDSC during melanoma growth. We subcutaneously injected 2 x 105 B16F10 and adminis-
tered topical 5% imiquimod cream (IQM) with or without i.p. injection of Dacarbazine (Dac).
FACS analysis revealed that the expression of B7H1 was significantly augmented both on splenic
(s-)MDSC and tumor-derived (t-)MDSC from IQM-treated mice. In contrast, the expression of B7H1
was normalized on s-MDSC from IQM/Dac treated mice though the B7H1 was still augmented on
t-MDSC. Interestingly, in parallel with the expression of B7H1 on s-MDSC, the administration of
IQM/ Dac significantly suppressed the growth of B16F10 melanoma. Next, to investigate the mech-
anisms responsible for the increased levels of B7H1 by IQM, we isolated CD11c+ cells or CD11b+
cells and examined the expression of IL-12 family mRNA using real-time PCR. CD11c from both
IQM treated and non-treated mice expressed p28 and EBI3, and the administration of IQM signif-
icantly increased p35 on CD11c. In addition, CD11b from tumor-bearing mice expressed the IL-
27R (gp130/WSX-1), indicating that B7H1 on CD11b might be augmented by IL-27. Since we pre-
viously reported the suppressive effect of B7H1 expressing MDSC by in vitro model, we further
investigated the therapeutic effects of blocking B7H1 molecules in vivo. As we expected based on
the in vitro data, i.p. injection of B7H1 antibody significantly suppressed the tumor growth in a dose
dependent manner. Our results suggest that s-MDSC and t-MDSC from B16F10 bearing mice express
B7H1 molecules that are augmented by topical IMQ, and normalized together with Dac in the s-
MDSCs, which induce the therapeutic effect of IMQ based therapy.
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p63, a p53 repressor in melanoma which confers chemoresistance and a poor prognosis
RN Matin, A Chikh, S Law Pak Chong, C Harwood and D Bergamaschi Centre for Cutaneous
Research, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom
The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly characterised. Muta-
tions in TP53 occur infrequently, yet the TP53 apoptotic pathway is abrogated. Despite numerous
attempts, there is still limited evidence to explain the molecular mechanism(s) of p53 inactivation
during melanomagenesis. The aims of this study were to investigate the biological role of TP63 and
explore its function in relation to dysregulation of the TP53 apoptotic pathway. Although p63 was
not expressed in primary melanocytes, upregulation of TP63 mRNA and protein was observed in
melanoma cell lines and clinical samples, providing the first evidence of significant p63 expression
in this lineage. We demonstrate that significant expression of TP63 in melanoma is responsible for
mediating chemoresistance. In response to genotoxic stress, endogenous p63 isoforms were sta-
bilised in both nuclear and mitochondrial subcellular compartments in association with increased
cytosolic release of cytochrome C confirming involvement of the mitochondrial intrinsic pathway.
Translocation of p63 to the mitochondria occurs through a co-dependent process with p53 whilst
accumulation of p53 in the nucleus was prevented by p63. Using RNAi technology, both isoforms
of p63 (TA and ΔNp63) were demonstrated to confer chemoresistance revealing a novel oncogenic
role for p63 in melanoma cells. Depletion of p63 resulted not only in increased release of APAF-1
but also positively affected the expression of pro-apoptotic BCl2 proteins. Our data demonstrates
that p53 repression could be due to direct binding interaction with p63 but also indirectly through
mdm2, whose expression is also affected by p63. Furthermore, expression of p63 in both primary
and metastatic melanoma clinical samples significantly correlated with melanoma-specific deaths
in these patients. Ultimately, these observations provide a possible explanation for abrogation of the
p53-mediated apoptotic pathway in melanoma, indicating novel approaches aimed at sensitising
melanoma to therapeutic agents
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Tobacco smoke enhances UVB radiation-induced and aryl hydrocarbon receptor-mediated
skin pigmentation
M Nakamura, Y Ueda, M Hayashi, T Furuhashi and A Morita Departments of Geriatric and
Environmental Dermatology, Nagoya City University, Nagoya, Japan
It is widely recognized that tobacco smoke causes pigmentation of the face, oral mucosa, and dor-
sal hands. Several studies have demonstrated that tobacco smoke causes premature skin aging
(e.g., smoker’s face) by direct effects on fibroblasts, and by inducing blood vessel narrowing and
loss of vitamin C. To our knowledge, however, no studies have examined the mechanisms under-
lying smoking-induced pigmentation of the skin. In the present study, we investigated whether
tobacco smoke enhances skin pigmentation by culturing normal human epidermal melanocytes
with tobacco smoke extract. When cultured with tobacco extract, melanocytes grew quite large and
produced more melanin. Although UVB-exposed melanocytes produced an equivalent amount of
melanin, no morphologic changes were observed. We used real-time PCR to evaluate melanocyte
activation by quantifying the expression of microphthalmia-associated transcription factor (MITF),
which is a master transcription factor related to melanocyte development and melanin production.
Although culturing the cells with tobacco smoke extract alone induced no significant changes, cul-
turing the cells with tobacco smoke extract combined with UVB irradiation significantly increased
MITF expression in a dose-dependent manner. Immunocytochemical studies revealed that these
activated melanocytes actively expressed aryl hydrocarbon receptors around the nuclear membrane.
The tobacco smoke-induced MITF activation was inhibited by RNA silencing of the aryl hydrocar-
bon receptor. This study provides the first evidence that tobacco smoke enhances sun-induced pig-
mentation by aryl hydrocarbon receptor-mediated mechanisms inside melanocytes. Previous reports
revealed that the role of melanin and melanocytes is not only photo protection, but also the rejec-
tion of free radicals. This reaction of melanocytes to tobacco smoke might be an important biologic
defense mechanism.
www.jidonline.org   S127
ESDR12_Abstracts-3  7/20/12  1:26 PM  Page S127
ABSTRACTS | Pigmentation and Melanoma 
728
Characterization of the Hippo Pathway in Melanoma: Focus on the effectors YAP and TAZ
F Nallet-Staub,1 C Gilbert,1 S Dodier,1 V Bataille,2 M Sudol,3 L Li,4 M Herlyn4 and A Mauviel1 1
Institut Curie, Orsay, France, 2 NHS, London, United Kingdom, 3 Geisinger Cancer Center,
Danville, PA and 4 Wistar Institute, Philadelphia, PA
YAP and its paralog TAZ are downstream effectors tightly regulated by the Hippo pathway in mam-
mals. Both have been shown to be amplified in certain human cancers and to promote cell prolif-
eration and epithelial-mesenchymal transition. To date, little is known about the status of the Hippo
pathway in melanoma. We thus undertook a broad analysis of Hippo pathway components expres-
sion in human melanoma cell lines and tumors, and characterized the capacity of YAP and TAZ to
control melanoma cell behavior. YAP and TAZ immuno-staining revealed mixed cytoplasmic and
nuclear staining for both proteins, with no clear difference between in benign nevi and human
melanoma samples (superficial spreading melanoma, nodular metastatic melanoma and malignant
melanoma in situ). Quantitative PCR identified variable expression of Hippo kinases LATS1/2 and
MST1/2 and their effectors YAP1/2 and TAZ across human melanoma cells, irrespective of their BRAF
or NRAS mutation status. Overall, TAZ mRNA levels were about 10-fold higher than those for
YAP2, and a 100-fold higher than those for YAP1. Western analysis revealed constitutive phospho-
rylation of LATS, MST, YAP and TAZ in several cell lines. Stable knockdown of TAZ and YAP by means
of lentiviral expression of specific shRNAs in four distinct cell lines did not alter their morphologi-
cal phenotype in culture, yet dramatically reduced anchorage-independent growth and capacity to
invade Matrigel. Also, YAP knockdown in 1205Lu reduced invasion in a model of skin reconstruct.
Inversely, YAP and TAZ overexpression increased melanoma cell invasiveness. Together, these results
indicate that both YAP and TAZ exert oncogenic activities in melanoma cells.
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Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A
P Cippà,1 J Kamarashev,3 S Segerer,2 J Chen,1 AK Kraus,1 PD Bardwell,4 L Feldmeyer5 and T Fehr1
1 Physiology, University of Zürich, Zurich, Switzerland, 2 Nephrology, University Hospital
Zurich, Zurich, Switzerland, 3 Dermatology, University Hospital Zurich, Zurich, Switzerland,
4 Abbott Bioresearch Center, Worcester, MA and 5 Dermatology, University Hospital
Lausanne, Lausanne, Switzerland
Bcl-2 (B-cell lymphoma 2) regulates the mitochondrial apoptosis pathway, and has a fundamental
function in cell survival, as demonstrated by the Bcl-2 deficient mice, showing accelerated lym-
phoid apoptosis, polycystic kidneys and hair depigmentation. Regulation of apoptosis in lympho-
cytes is important for de-velopment and homeostasis of the adaptive immune system. Calcineurin
is a critical factor in T cell ac-tivation but is also involved in the regulation of naïve T cell survival
through a modulation of Bcl-2 expression. Therefore, suppressing calcineurin might potentiate the
pro-apoptotic effect of small molecule Bcl-2 inhibitors. We investigated the effect of a blockade of
the calcineurin/NFAT pathway on the pro-apoptotic potency of ABT-737 in mice and showed that
the reduction in Bcl-2 expression in lymphocytes exposed to inhibitors of the calcineurin/nuclear
factor of activated T cells (NFAT) pathway correlated with an increased sensitivity to the Bcl-2 inhibitor
ABT-737 in vitro. Moreover, the calcineurin inhibitor cyclosporine A potentiated the pro-apoptotic
effect of ABT-737 in vivo on one hand on lymphocytes, and on the other hand on melanocytes: in
combination with cyclosporine A, ABT-737 partially reproduced the phenotype of Bcl-2 deficient
mice, char-acterized by a generalized fur depigmentation as a result of melanocyte loss. Survival of
melanocyte stem cells depends on Bcl-2. The i.p. application of ABT-737 induced melanocyte deple-
tion and hair depigmentation, increased in combination with CsA, suggesting that CsA sensitized
the melanocytic cells to the effect of ABT-737 in a similar way as found in lymphocytes.
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A promising LCM virus based vaccine vector: mechanisms and efficacy against melanoma
S Ölschläger, M Gilliet and L Flatz Department of Dermatology, University Hospital Center
and University of Lausanne, Lausanne, Switzerland
The incidence of malignant melanoma is increasing at a faster rate than any other cancer and cur-
rently accounts for 4% of all newly diagnosed cancers. While early-stage lesions are curable with
appropriate surgical resection, once melanoma metastasizes to regional lymph nodes or distant sites,
the prognosis is poor. Chemotherapy regimens have thus far had little impact on overall survival of
metastatic melanoma patients; therefore much effort is being devoted to the search for alternative
treatment options, including immunotherapy. We assessed in this context the suitability of a recently
described novel replication defective vaccine vector based on the prototypic arenavirus lympho-
cytic choriomeningitis virus, which efficiently induces potent CD4 and CD8 T cell responses against
a variety of model antigens. Albeit a virus vector of murine origin, we show that it can readily infect
human peripheral blood mononuclear cells and thereby activates dendritic cells, which is demon-
strated by an upregulation of CD86. Furthermore, we show that human CD8 T cells can efficiently
be primed in vitro. Using the B16 melanoma mouse model, we demonstrate efficient control of
tumor growth by therapeutic vaccination. Several different virus vectors were constructed to deter-
mine the optimal heterologous or homologous melanoma antigen. These experiments suggest a
potential follow-up in patients, i.e. a phase 1 clinical trial.
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Novel Mechanism Involved In Temporal Regulation Of Skin Pigmentation Homeostasis
P Ganju,1 VT Natarajan,2 A Singh,1 V Vijayan,3 P Dani,1 HK Kar,4 K Natarajan,5 CJ Gadgil,3 R Rani1
and RS Gokhale2 1 National Institue of Immunology, New Delhi, India, 2 Institute of Genomics
and Integrative Biology, Delhi, India, 3 National Chemical Laboratory, Pune, India, 4 Dr Ram
Manohar Lohia Hospital, New Delhi, India and 5 Jawaharlal Nehru University, New Delhi,
India
Epidermal skin pigmentation is an intricate process that involves a complex interplay between
melanocytes and keratinocytes. The synthesis of melanin pigment in melanosomes proceeds in dis-
tinctly identifiable stages inside melanocytes. The mature melanosomes are then transferred to ker-
atinocytes providing the visually apparent skin color. Recent insights into pigmentary process have
revealed the role of MITF as the central factor involved in maintaining melanocyte biology and
melanosome synthesis and transport. The negative regulators of pigmentation also function by
altering levels of MITF. However, presently no temporal mechanism of hypopigmentation has been
described. In order to delineate factors involved in melanogenesis and the process of melanosome
maturation, we have developed a cell-autonomous reversible pigmentation-depigmentation model
system. We have investigated differences in the gene-expression profiles of cells at different stages
of pigmentation and identified a novel factor that causes reversible hypopigmentation of melanocytes.
We demonstrate that this factor decreases the levels of melanogenic proteins and stalls melanosomes
at an early stage of maturation. Remarkably, this process of hypopigmentation is manifested even
in the presence of MITF activating agents, suggesting this factor seemingly operates by circumventing
MITF. Removal of the factor reinitiates melanosome maturation and the melanocytes regain their
normal cellular programming. The hypopigmenting effect of this factor can be replicated in the
mouse transgenic as well knock-out models. Our studies thus delineate a mechanism of melano-
genesis regulation that might be involved in maintaining human skin pigmentation homeostasis.
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Will PAXgene Substitute Formalin? A Morphological and Molecular Comparative Study Using
a New Fixative System
B Belloni,1 C Lambertini,2 P Nuciforo,2 J Phillips,3 E Bruening,3 S Wong3 and R Dummer1 1
Dermatology, University Hospital Zurich, Zurich, Switzerland, 2 Novartis Oncology
Translational Medicine, Basel, Switzerland and 3 Molecular MD, Portland, OR
Formalin fixation and paraffin embedding present the standard procedures for conserving clinical
tissues for histological analysis. However, molecular analysis is impaired by the cross linking prop-
erties of formalin. The PAXgene tissue system (PreAnalytix, Switzerland) is a new formalin-free tis-
sue collection device. Aims: In this study we aimed to evaluate this new tissue preservation tech-
nique in comparison to formalin fixation and fresh frozen tissue samples. Methods: 12 melanoma
biopsy samples were divided and fixed simultaneously with formalin, PAXgene, or fresh frozen in
liquid nitrogen and analysed with regard to morphology, immunohistochemistry as well as DNA
and RNA content and quality. Markers of melanocytic differentiation as well as tumor cell prolifer-
ation were used. Results: Morphology was well preserved in PAXPE samples. However, 5 out of 11
immunohistochemical markers showed significantly lower overall staining and staining intensity
with PAXPE tissues in comparison to FFPE. Increasing membrane permeability through adding a
detergent did proportionally increase staining intensity in PAXPE samples. Amplification of differ-
ent mRNA amplicons showed a direct relationship with the size of the amplicon with greater tem-
plate integrity observed in PAXPE samples. Sequencing and mutational analysis of DNA samples
were comparable for all the different fixation methods, while the level of DNA fragmentation seemed
to be lower in PAXPE compared to FFPE tissues. Conclusion: The switch from formalin to PAXgene
fixation would require a re-evaluation of immunohistochemical markers and staining procedures
originally developed for FFPE tissues. Our data demonstrate that PAXPE fixation offers some advan-
tages concerning molecular analysis. However, these advantages would not justify substituting for-
malin fixation in any routine pathology lab.
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Notch4 Mediated Regulation of Slug and Twist1 in Melanoma
E Bonyadi Rad, U Popper, C Wels, DR Menon and H Schaider Department of Dermatology,
Medical University of Graz, Graz, Austria
Notch signaling exerts both oncogenic and tumor-suppressive properties in solid tumors, which is
context dependent. Epithelial-mesenchymal transition regulators like Slug and Twist1 are important
for tumor progression. We investigated, whether Notch4 signaling affects protein and transcript
levels of Slug and Twist1 in melanoma cell lines with consequences for cadherin levels. Lentiviral
overexpression of the intracellular domain of Notch4 (NICD4) resulted in a decrease of Slug and
Twist1 protein levels and real time PCR showed a decrease of RNA transcripts. Gel shift assays and
ChIP assays demonstrated binding of the key regulator of Notch signaling CSL to consensus sites
upstream the transcription start site of the Slug and Twist1 promoter in non-transduced cells. Fur-
ther co-immunoprecipitation assays showed binding of NICD4 to CSL in non-transduced cells. Over-
expression of NICD4 led to drastic phenotypic changes in a melanoma cell line with spindle cell
morphology (WM9), leading to cobblestone cells. Concomitantly, a decrease in N-cadherin and a
profound increase in E-cadherin levels at mRNA levels and partially at protein levels were observed.
Our data suggest that Notch4 is suppressing Slug and Twist1 expression in melanoma and leads to
phenotypic changes with alterations in cadherin expression.
S128 Journal of Investigative Dermatology (2012), Volume 132
ESDR12_Abstracts-3  7/20/12  1:26 PM  Page S128
Pigmentation and Melanoma | ABSTRACTS
734
Fibroblasts regulate both physiological and pathological pigmentation of skin in vitro and in
vivo
M Cario-Andre,1 K Ezzedine,3 C Pain,1 V Guyonnet-Dupérat,2 A Bibeyran2 and A Taieb3 1
University V segalen, Bordeaux, France, 2 INSERM 1035, Bordeaux, France and 3 dermatol-
ogy, Universitary Hospital, Bordeaux, France
We have previously described that white human skin or white human epidermal reconstructs
xenografted onto nude mice could become black or totally white and that FGF2 and cytokeratin 5
were overexpressed in epidermis of hyperpigmented samples, and that these changes were under
dermal influence. In some dermatological disorders, such as erythema multiforme and scleroderma,
some evidence from our group suggests that pigmentary post inflammatory change may involve sim-
ilar dermo-epidermal mechanisms. In particular, we observed that scleroderma fibroblasts could
induce or repress pigmentation. Since all these data point to a key role of FGF2, we used our model
of epidermal reconstruction to analyze the impact of FGF2 on skin structure and pigmentation using
FGF2 overexpressing fibroblasts or/and keratinocytes. We observed that secreted FGF2 and epi-
dermal FGF2 were tightly regulated since their amount was not drastically increased in contrast with
3 fold increase of FGF2 secretion for transduced monolayer cultures . Patterns of expression of epi-
dermal FGF2 were different in non transduced reconstructs made with passage 3-4 fibroblasts (LPF)
and passage 10 fibroblasts (HPF). Overexpression of FGF2 in reconstructs with LPF did not modify
the pattern of expression of FGF2 whereas HPF induced a pattern of expression of FGF2 which was
close to that observed with LPF. FGF2 supplementation in epidermal reconstructs induced pig-
mentary changes and increase expression of cytokeratin 5 whereas overexpression by fibroblasts or
keratinocytes of FGF2 did not induce such changes suggesting that FGF2 was tightly regulated in
3D reconstructs. In these experiments, we also confirmed a link between cytokeratin 5 and pig-
mentation via MITF. In conclusion, our data associated with clinical observations of pigmentary dis-
orders support the hypothesis that fibroblasts modulate pigmentation downstream FGF2 in the epi-
dermal compartment
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Kinesin family member 20A as a novel melanoma associated antigen
J Yamashita, S Fukushima, N Honda, M Jinnin, Y Inoue and H Ihn Department of Dermatology
and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Malignant melanoma is often associated with early metastatic spread and high level of resistance
to several strategies. Several melanoma-associated antigens have been identified and the clinical
trials utilizing these antigens were conducted. However, the satisfying results have not been obtained.
Recently, antibody against cytotoxic T-lymphocyte antigen 4 has demonstrated consistent activity
against advanced malignant melanoma. Immunotherapy is thought to be candidate modalities for
advanced malignant melanoma. Kinesin family member 20A (KIF20A) was identified for pancre-
atic ductal carcinomas based on a cDNA microarray analysis and reported that could be a prom-
ising immunotherapeutic target for pancreatic cancer. KIF20A is highly expressed among the other
cancers such as lung cancer, bladder cancer, cholangiocellular carcinoma and breast cancer and
was detected its exclusive expression in the testis and thymus in normal tissues. And KIF20A is sus-
pected to be involved in cancer carcinogenesis. Clinical vaccine trials using KIF20A peptide had
been conducted against pancreatic cancers. In this study, we investigated KIF20A expressions in
malignant melanomas.We conducted RT-PCR and western blotting in 10 melanoma cell lines and
a nevus cell line. All melanoma cell lines and a nevus cell line showed KIF20A mRNA and protein
expression. We also investigated 51 primary melanomas, 9 metastatic melanomas and 26 nevi by
immunohistochemical analysis and analyzed 28 primary melanomas, 10 metastatic melanomas and
10 nevi by real time PCR. KIF20A was expressed in 59% of primary melanomas, 67% of metasta-
tic melanomas and 11% of nevi by immunohistochemical analysis. And 64% of melanomas, 80%
of metastatic melanomas and 60% of nevi were positive for KIF20A mRNA. Primary melanoma pos-
itive for KIF20A showed significant greater thickness and KIF20A positive patients tended to develop
earlier recurrence. These results suggested that immunotherapy utilizing KIF20A could be a treat-
ment option for malignant melanoma.
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Development of a full thickness pigmented reconstructed skin : evidence for an essential
role of dermal components in regulating the pigmentation
C Duval, C Cohen-Dellarre, C Chagnoleau and F Bernerd L Oreal Research & Innovation,
Clichy, France
Three-D pigmented reconstructed epidermis are useful tools for research in pigmentation and eval-
uation of pro- or anti-pigmenting agents. However, the presence of biologically active dermal com-
ponents and fibroblasts is now recognized as being important for regulation of pigmentation. The
first phase of this study aimed at reconstructing a complete skin substitute, including an epidermis
with melanocytes laid onto a dermal equivalent containing fibroblasts. The morphology and local-
ization/distribution of melanocytes showed excellent features. Melanogenesis led to synthesis of
melanin granules which were transferred to keratinocytes. Melanocytes from donors of various
phenotypes, from light to dark skin, were successfully integrated resulting in a pigmentation simi-
lar to the original skin color type. The second phase aimed at checking the functionality of the model
and its ability to respond to well known pro-pigmenting agents. The reconstructed skin was treated
with αMSH or forskolin resulting in an increase in pigmentation, a decrease in luminance (L) val-
ues and a significantly higher melanin content. The impact of dermal fibroblastic compartment on
the level of pigmentation was then investigated. First, pigmentation of the reconstructed pigmented
skin samples produced with or without viable fibroblasts was analyzed. Absence of fibroblasts
induced a drastic hyperpigmentation, thus showing the important role of these cells in regulating
the pigment synthesis. Then, reconstructed skin models were made with dermal fibroblasts from
donors of various age and from photoprotected or photoexposed sites. Our results indicate that the
intensity of the constitutive pigmentation solely depends on the characteristics of the fibroblast strain.
Altogether, this data illustrates the interest of such a full thickness pigmented skin model including
melanocytes, keratinocytes and dermal fibroblasts to study regulation of pigmentation and empha-
sizes the role of the dermal compartment.
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Three dimensional melanoma treatment using the death ligand TRAIL
H Voersmann,2 N Peters,2 S Beissert1 and D Kulms1 1 Experimental Dermatology, University of
Dresden, Dresden, Germany and 2 Institute of Cell Biology and Immunology, University of
Stuttgart, Stuttgart, Germany
Despite remarkable efforts, metastatic melanoma still presents with significant mortality. Recently,
treatment strategies are increasingly replenished by more cancer specific regimens, involving death
ligands and drugs interfering with cell signalling. To scrutinize the effects of death ligand treatment
on melanoma cell survival various melanoma cell lines were treated with TAIL. It was shown that
the majority of the melanoma cell lines stayed resistant against TRAIL-induced apoptosis. Interest-
ingly, TRAIL resistance could be broken by additional treatment with UVB or cisplatin. At the molec-
ular level TRAIL resistance was due to incomplete processing of caspase-3 through binding of anti-
apoptotic XIAP. Upon co-stimulation with DNA damaging agents apoptosis induction coincided
with depletion of XIAP and full caspase-3 processing via: 1. NFkappaB-dependent repression of
anti-apoptotic genes, including XIAP, and 2. Caspase-3-mediated cleavage of XIAP initiating a pos-
itive feedback loop. To extend our findings on melanoma cell sensitization towards TRAIL to con-
ditions mimicking the in vivo environment we have generated a novel organotypic tumor model.
We did so by inserting melanoma spheroids of defined sizes (500 μm in diameter) into organotypic
full skin models. Treatment of melanoma spheroids with either TRAIL and UVB or TRAIL and cis-
platin was shown to selectively kill tumor cells in an apoptotic fashion, while sparing the surrounding
primary tissue. Together, these data indicate that TRAIL can be successfully used in combination
with UVB irradiation or cisplatin to inhibit melanoma growth. Additionally, this organotypic tumor
model provides a useful tool for pre-clinical analysis of tailored combination therapies to fight
melanoma.
735
Clinical grade generation of tumor-specific CD4+ T helper lymphocytes for adoptive
immunotherapy against malignant melanoma-antigens
CN Boss,1 S Kayser,2 S Malaika Rittig,3 B Weide,2 C Garbe,2 T Feuchtinger2 and M Röcken1 1
Dermatology, University of Tuebingen, Tuebingen, Germany, 2 University Children’s Hospital,
University of Tuebingen, Tuebingen, Germany and 3 Oncology, University of Tuebingen,
Tuebingen, Germany
Adoptive T cell transfer is considered as therapeutic option for the treatment of patients with metasta-
tic malignant melanoma. T lymphocytes for adoptive T cell transfer are generated ex vivo and are
re-infused into the patient. Recent evidence suggests that CD4+ T helper (Th1) lymphocytes are of
great importance for those therapeutic strategies as they orchestrate the response of cytotoxic T
lymphocytes and can impair tumor growth and angiogenesis through cytokine signaling. The aim
of this study was to design a GMP conform protocol for the generation of melanoma-specific CD4+,
interferon-γ-producing T helper (Th1) lymphocytes. PBMCs from healthy donors were primed with
NY-ESO-1 or Survivin 15-mere overlapping peptide mixes. After 2 weeks of stimulation with IL-2,
we enriched IFN-γ producing cells with the IFN-γ capture technique. Then cells were expanded over
2 weeks with a defined cytokine cocktail prior to analysis. We could generate cell products with
up to 3 x 109 cells, containing NY-ESO-1 or Survivin-specific, CD4+ Th1 lymphocytes. Furthermore
we found that the generated cells produced a Th1 cytokine profile after restimulation with the
melanoma-antigen and that those cytokines such as interferon-γ could impair tumor growth. This
could be manifested by cell cycle analysis of melanoma cells and other tumor entities. In summary,
GMP conform generation of tumor-specific CD4+ T helper (Th1) lymphocytes for the use in
immunotherapy against metastasized malignant melanoma was established and the effects of Th1
cytokines on melanoma cells were analysed.
739
CCR5 expression on melanoma cells affects the disease progression
R Hino, H Fueki-Yoshioka, R Yoshiki and M Nakamura Department of Dermatology, University
of Occupational and Environmental Health, Kitakyushu, Japan
Many chemokines show antitumor activity by stimulating immune cells, however, other chemokines
promote tumor growth and metastasis by direct growth stimulation, enhancing cell motility, or angio-
genesis. We found that some isolated tumor cells from advanced melanoma patients strongly express
CCR5. Immunohistochemically, patients of melanoma expressing CCR5 in primary tumor have
poorer survival rate than CCR5 negative cases. We sought the biological significance of CCR5 expres-
sion on melanoma cells. When we incubated CFSE-conjugated melanoma cell line WM-115 cells
with CCR5 ligands CCL3 and CCL5 for 7 days, the percentage of CFSElow cells, which is consid-
ered as proliferated cells, were increased in CCL5 added WM-115 cells. To confirm these findings,
we sorted CD133+ or CD133- cells from isolated tumor cells and analyzed the CCR5 expression.
Although CD133 expression is known as a cancer stem cell marker, many reports indicated that
CD133 expression on melanoma cells strongly correlates tumorigenesis and chemoresistance. In
CD133 positive fraction, the percentage of CCR5 positive cells is higher than negative fraction. Fur-
thermore, WM-115 cells can produce CCL3 and CCL5. Additionally, we previously reported that
CCR5 ligands enhance the production of TGF-β by melanoma cells. Taken together, our present find-
ings suggest that CCR5 on melanoma cell may play a crucial role for immune escape, and prolif-
eration in patients with malignant melanoma. These findings suggest also that the CCR5 and its lig-
ands promote tumor progression in an autocrine/paracrine manner. We conclude that CCR5
expression on melanoma cells correlates the disease progression and prognosis. Further trial is
needed whether CCR5 can be a therapeutic target of melanoma.
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The presence of red hair MC1R variants enhance melanoma sun-induced susceptibility in a
CDKN2A skin-humanized mice model of cutaneous familiar melanoma
M Escámez,1 J Puig-Butille,2 C Badenas,2 P Aguilera,2 C Carrera,2 L Martínez-Santamaría,1
M Retamosa,1 ÁLVARO Meana,3 M Del Río1 and S Puig2 1 Regenerative Medicine Unit, CIEMAT
and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) U714
Department of Bioengineering, Universidad Carlos III, Madrid, Spain, 2 Melanoma Unit,
Hospital Clinic & IDIBAPS (Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer) and
Centro Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain
and 3 Tissue Engineering Unit, Centro Comunitario de Sangre y Tejidos de Asturias (CCST)
and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) U714,
Oviedo, Spain
Melanoma is the leading world cause of death from skin cancer being a polygenic multifactorial
disease involving environmental factors and genetic susceptibility. High susceptibility germline
mutations in CDKN2A and CDK4 genes combined with low-medium penetrance MC1R gene vari-
ants have been associated to melanoma-prone families. The p.G101W, the most common CDKN2A
mutation in Mediterranean European Countries is also frequent in USA. Additionally, MC1R vari-
ants responsible for red-hair increase melanoma risk in p.G101W melanoma families. We have
developed a skin-humanized mouse model by orthotopic transplantation of a bioengineered skin
containing keratinocytes/melanocytes and fibroblasts from members of two melanoma-prone fam-
ilies: two were p.G101W carriers and two MC1R red-hair variant carriers. The model faithfully repro-
duced the physiopathological characteristics of the donor’s skin in terms of photo-type, DNA dam-
age (dimmers) and UV-response (p53) induction. Consequently, double mutant skin with CDKN2A
p.G101W mutation and two red-hair polymorphisms was more susceptible to sun-induced melanoma
through the production of pyrimidine dimmers and reduction of p53 dependent DNA repair.
741
Differential sensitivity of pigmented and non pigmented melanoma cell lines to vitamin D3
analogs Wasiewicz T, Slominski AT, Kutner A, Zmijewski MA Department of Histology, Med-
ical University of Gdansk, Gdansk, Poland Department of Pathology and Laboratory Medi-
cine, UTHSC, Memphis, TN, USA; Pharmaceutical Research Institute, Warsaw, Poland
M Zmijewski,1 T Wasiewicz,1 A Slominski2 and A Kutner3 1 Department of Histology,,Medical
University of Gdansk, Gdansk, Poland, 2 Department of Pathology and Laboratory Medicine,
University of Tennessee Health Science Center, Memphis, TN and 3 Pharmaceutical Research
Institute, Warsaw, Poland
Melanoma cause majority of skin cancer related deaths, but still surgical intervention is preferred
method of treatment. Vitamin D was shown to inhibit growth and induce differentiation of melanoma
cancer cells, but excessive vitamin D intake leads to hypercalcaemia. Vitamin D analogues with
modified side-chain show potentially low calcemic activity, but their antiproliferative properties
need to be evaluated. Experiments were performed using mouse melanoma cell line (B16F10) and
human melanoma cell lines (SKMEl 188, A 375 and WM 98) and antiproliferative properties of
vitamin D analogs: calcipotriol, calcifediol, pD3, 21-OHpD3 viability tests (MTT, SRB) were tested.
Expressional analysis of the genes coding proteins responsible for vitamin D metabolism (CYP24A1,
CYP2R1, CYP3A4, CYP27B1, CYP27A1) and function (VDR, RXR, Pdia3) was performed using
PCR or qPCR and selectively confirmed by Western-blot. It seems that activity of vitamin D analogs
depends on the level of expression of vitamin D receptor and co-receptor. In case of human melanoma
cell lines, WM 98 and A375 show much higher sensitivity to vitamin D analogs treatment when
compared to SKMEL 188. Explanation of this phenomenon could be different pattern of VDR iso-
forms expressed in those cell lines. There are also indication that short side-chained vitamin D ana-
logues treatment did not resulted in efficient translocation of VDR receptor despite significant antipro-
liferative activity of those compounds. Summarizing differential gene expression may influence
sensitivity of melanoma cells to vitamin D analogues and their activity may not be exclusively
dependent on VDR receptor.
742
Detection of prohormone convertase PC5/6 in normal and transformed human melanocytes
N Weiss, A Stegemann, C Weishaupt, T A. Luger and M Böhm Dept. of Dermatology, University
of Münster, Münster, Germany
Prohormone convertases (PCs) are a family of Ca2+dependent serine proteases which include
PC1/PC3, PC2, PC4, paired basic amino acid-cleaving enzyme 4, PC5, PC7, subtilisin kexin isoen-
zyme-1 (SKI-1), and neural apoptosis-regulated convertase-1. Until now, the role of PCs, especially
PC1/3 and PC2, in pigment cells has been mainly investigated in the context of processing of proo-
piomelanocortin, the precursor for alpha-melanocyte-stimulating hormone. However, there is increas-
ing evidence that PCs may play an important role in cellular transformation, acquisition of a tumori-
genic phenotype and metastasis in a number of solid tumors. We recently identified SKI-1 as a
possible novel target for melanoma therapy. To check if additional members of the PC family could
play a role in melanoma biology we performed an in vitro expression analysis of PC5/6 in normal
human melanocytes (NHM) and a panel of 8 human melanoma cells lines derived from different
stage of disease progression. Expression of PC5/6 was examined by semi-quantitative RT-PCR, real-
time RT-PCR, Western immunoblotting and immunofluorescence analysis. PC5/6 expression was
significantly increased at mRNA level in 6 out of 8 melanoma cell lines compared to NHM. This
could be confirmed at protein level. Immunofluorescence analysis disclosed cytoplasmic localiza-
tion of PC5/6 in melanoma cells. Via in silico promoter analysis we detected several putative tran-
scription factor binding sites for transcription factors that are typically activated by melanocyte mito-
gens as well as by extracellular and intracellular stressors. However, only tunicamycin, an
endoplasmic reticulum stressor, increased PC5/6 expression in NHM. Our preliminary data indi-
cate that PC5/6 is expressed by human pigment cells in vitro with more abundance of PC5/6 mRNA
and protein in melanoma cells. At present we focus on immunohistochemical studies of PC5/6 in
melanoma specimens as well as on functional analysis of PC5/6 using gene knock-down. These data
should clarify if PC5/6 is a novel target for melanoma therapy.
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IL-2 therapy is accompanied with increased number of activated T regulatory lymphocytes in
peripheral blood of melanoma patients
A Jalili, A Moser, A Stelmaszczyk-Emmel, M Pashenkov, C Wagner, G Stingl and SN Wagner
Department of Dermatology, Medical University of Vienna, DIAID, Vienna, Austria
Melanoma is the most malignant skin cancer. In opposite to targeted therapies immunotherapies
are accompanied with less significant but long lasting clinical responses. Here, regulatory T lym-
phocytes (Tregs) are shown to be of significant importance deciding for the outcome of clinical
responses. The aim of our study was to evaluate the frequency of Tregs in human melanoma patient’s
after IL-2, interferon, conventional chemotherapies and CpG vaccine treated as compared to untreated
patients and healthy controls. Tregs are considered to be CD4+/CD25high/FoxP3+. CD69 is known
as activation and CD62L as LN homing marker. In healthy controls, of PBMCs were 1%
CD4+/CD25high. 87% of CD4+/CD25high were FoxP3+ (Tregs). 73% of CD4+/CD25high/FoxP3+
cells were expressing CD62L where expression of the CD69 was 0,2%. The frequency of Tregs in
peripheral blood of melanoma patients was comparable to healthy controls. Interestingly, the expres-
sion of CD69 by Tregs was significantly higher in melanoma patients as compared to healthy con-
trols, however no difference in the expression of CD62L was observed. IL-2 therapy was accom-
panied with increased number as well as expression of CD69 by Tregs as compared to untreated as
well as interferon or CpG vaccine but not chemotherapy treated patients. In opposite to our expec-
tation, increased frequency of Tregs in IL-2 treated patients was correlated with better clinical response.
Our results demonstrate that: a) the frequency of activated Tregs is significantly higher in melanoma
patients as compared to healthy controls, b) IL-2 therapy is accompanied with increased frequency
of activated Tregs as compared to untreated, interferon or CpG vaccine treated patients and finally,
c) increased frequency of activated Tregs in IL-2 treated patients was accompanied with better clin-
ical response and overall survival. Our results demand further exploration of the role of Tregs in
melanoma patients treated with different immunotherapeutic strategies.
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The rs2910164 G>C polymorphism in microRNA-146a is associated with the incidence of
malignant melanoma
S Fukushima, T Iwakiri, M Jinnin, J Yamashita, N Honda, Y Inoue and H Ihn Dermatology and
Plastic Surgery, Kumamoto University, Kumamoto, Japan
MicroRNA-146a (miR-146a) is one of the microRNAs (miRNAs) implicated in the pathogenesis of
various cancers. Recently, single nucleotide polymorphisms (SNPs) located in miRNAs themselves,
so-called MIRSNPs, have attracted attention for their possible involvement in the pathogenesis of
various diseases. Such MIRSNPs may have functional roles, due to the alteration of miRNAs. In this
study, we investigated whether MIRSNP rs2910164 in miR-146a is involved in the pathogenesis of
malignant melanoma (MM). DNAs were collected from 50 patients with MM and 107 controls and
genotyped by polymerase chain reaction-restriction fragment. We found significant differences in
the frequency of genotype distribution between controls and patients with MM. On the other hand,
we could not find any significant difference in relationship between genotype distribution and clin-
ical manifestation. In addition, the minimum free energy between miR-146a and its complemen-
tary strand with G allele is estimated at -26.8 kcal/mol while that of C allele is at -24.0 kcal/mol,
suggesting that the MIRSNP rs2910164 is functional. Taken together, miR-146a may be involved in
the morbidity of MM, and patients with CG genotype have a higher risk to develop MM.
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Protein-protein interaction networks in cocultured melanocytes and keratinocytes regarding
the genomic status of CDKN2A and MC1R genes
JA Puig-Butillé,1 G Tell,2 M Escamez,3 F Garcia,4 L Martinez,3 C Badenas,1 J Dopazo,4 M Del Río3
and S Puig1 1 Melanoma Unit, Hospital Clinic & IDIBAPS (Institut d’Investigacions
Biomèdiques Agustí Pi i Sunyer), Centro Investigación Biomédica en Red en Enfermedades
Raras (CIBERER), Barcelona, Spain, 2 Melanoma Unit, Hospital Clinic & IDIBAPS (Institut
d’Investigacions Biomèdiques Agustí Pi i Sunyer), Barcelona, Spain, 3 Medicina Regenerativa.
Div.Biomedicina Epitelial, CIEMAT, Centro Investigación Biomédica en Red en Enfermedades
Raras (CIBERER), Madrid, Spain and 4 Bioinformatics Department, Centro de Investigación
Príncipe Felipe (CIPF), Centro Investigación Biomédica en Red en Enfermedades Raras
(CIBERER), Valencia, Spain
To identify molecular networks associated to presence of either germline mutations in CDKN2A or
variants in MC1R genes which may be related with the biological impact of both genes into melanoma
susceptibility. Expression data from cocultured keratinocytes and melanocytes from CDKN2A mutant
melanoma families was extracted and analyzed using Whole Human Genome Microarray 4x44K
(Agilent). Two patients were CDKN2A mutation carriers and two were MC1R red hair colour vari-
ants carriers. Differential gene expression data (1535 transcripts deregulated in CDKN2A mutated
cells and 3570 in MC1R variants carriers) were analyzed by SNOW (a statistical analysis of pro-
tein–protein interaction networks). Statistically significant networks were identified among down
regulated genes. Overall, 24.7% of them in CDKN2A mutants and 27.8% in MC1R variants carri-
ers were localized in networks. The network cores were genes involved in autophagy process
(e.g.GABARAPL2,SQSTM1 and LC3). Moreover, a network formed by 28.5% of upregulated tran-
scripts in MC1R variants cells also reaches the significance. In this case, the network core was com-
posed by genes playing a role in oxidative phosphorylation and mithocondrial ribosome (e.g., GBAS
and ICT1). Our results suggest that variants in both MC1R and CDKN2A gene promote autophagy
deregulation in skin cell types. Also, we have identified genes involved in the elevated cellular lev-
els of reactive oxygen species in MC1R variant carriers.
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Carraghenane λ attenuates human melanocyte dendricity in melanocytes/keratinocytes co-
culture model
P Sextius,1 E Prud’homme,2 K Da Silva,3 D Fagot3 and B Bernard1 1 L’Oréal Research and
Innovation, Clichy, France, 2 L’Oréal Research and Innovation, Chevilly-Larue, France and 3
L’Oréal Research and Innovation, Aulnay-sous-Bois, France
Skin pigmentation results in part from the transfer of melanin-containing melanosomes from
melanocytes to neighboring keratinocytes. Melanosome transfer to keratinocytes closely relates to
melanocyte dendricity. Some previous works indicate that glycans expressed by these epidermal
cells are major actors in genesis of dendrites and, further, in melanosome transfer to keratinocytes.
Therefore, the process of dendrites’ generation presents opportunities to influence human skin pig-
mentation through topical application of cosmetic products. Melanocytes/ keratinocytes co-culture
model was used to examine dendricity response to exogenous factors. In this model, melanocyte
dendricity could be induced by IBMX, a cAMP elevating agent which is also known for inducing
melanosome transfer. Under such experimental conditions, addition of a not cytotoxic dose of a
reference linear sulfated polysaccharide, carraghenane λ, leads to a dose-dependent decrease in
melanocyte dendricity. These results suggest that melanocyte dendricity can indeed be modulated,
in vitro, by melanocyte environment and more specifically by the presence of sulfated polysac-
charides. These results pave the way to a new strategy aimed at skin lightening.
748
Lecithin/retinol acyltransferase as a key enzyme in vitamin A metabolism maintaining insen-
sitivity to retinoids in malignant melanoma
PM Amann,1 K Czaja,1 AV Bazhin,2 R Rühl,3 SB Eichmüller,4 HF Merk1 and JM Baron1 1
Department of Dermatology and Allergology, RWTH Aachen University, Aachen, Germany, 2
Department of General Surgery, University Hospital Heidelberg, Heidelberg, Germany, 3
Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen,
Hungary and 4 Division of Translational Immunology, German Cancer Research Center,
Heidelberg, Germany
Adjuvant chemotherapeutical treatments for human malignant melanoma are rarely effective. Even
therapeutics such as vitamin A (all-trans retinol, ATRol) and its derivates (retinoids) which are suc-
cessfully used to treat other forms of cancer are ineffective. Retinoids are able to influence cell
growth, differentiation and apoptosis by controlling various signaling pathways and are regarded to
be important in the context of tumor development and progression. Our aim was to investigate the
significance of vitamin A metabolism for tumor biology and retinoid resistance in human malig-
nant melanoma. We could identify human melanoma specific alterations in the expression and
activity of enzymes involved in retinoid metabolism. One of these key enzymes is lecithin/retinol
acyltransferase (LRAT) which is expressed in melanoma cells but not in melanocytes catalysing the
esterification of ATRol. We could show that stable LRAT knockdown in the human melanoma cell
line SkMel23 lead to changes in gene regulation after retinoid treatment analysed by microarray
analysis. These results were confirmed by qRT-PCR revealing an upregulation of retinoid-regulated
genes like CYP26A1 and STRA6 expression in LRAT knockdown cells. LRAT knockdown restored
their sensitivity to retinoids analysed by cytotoxicity tests and proliferation assays. Therefore, we
propose that the removal of ATRol in melanoma cells by LRAT leads to a disturbance in cellular
retinoid level and protects tumor from retinoids. Consequently, the decreasing cellular amount of
all-trans retinoic acid and its precursor molecules should result in a change of gene regulation.
Inhibition of LRAT activity could be a promising strategy to overcome retinoid insensitivity in human
melanoma cells.
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The expression of hyaluronan, CD44 and hyaluronidases in cutaneous melanocytic tumors
H Siiskonen,1 M Poukka,1 K Tyynelä,2 R Tammi,1 R Sironen2 and S Pasonen-Seppänen1 1 Institute
of Biomedicine, University of Eastern Finland, Kuopio, Finland and 2 Institute of Clinical
Medicine/Clinical pathology, Kuopio University Hospital, Kuopio, Finland
Aberrant expression of hyaluronan (HA) and its receptor, CD44, implicates aggressive disease pro-
gression and metastatic potential in many cancers. In this retrospective study, we characterized the
expression levels of CD44, hyaluronan degrading enzymes (hyaluronidases, HYAL1-2), and corre-
lated their expression to HA in the different stages of primary skin melanoma. Superfically (pT1) and
deeply (pT4) invasive melanoma, Breslow < 1mm (n=17) and Breslow > 4mm (n=19), in situ
melanoma (n=18) and dysplastic nevi (n=29) were analyzed for HA staining and CD44, HYAL1
and HYAL2 immunoreactivity in paraffin tissue sections and compared to benign nevi (n=29). The
tissue area for HA, CD44 and HYAL1/HYAL2 positive staining was estimated with a five-level scor-
ing from 0-4 and the staining intensity of melanocytic cells was evaluated with a four-level scoring
(0-3; no color, weak, moderate and strong) by two independent observers. Compared to benign nevi
and in situ melanoma, HA staining intensity and coverage were clearly reduced in invasive
melanocytic lesions. Strong HA staining intensity was detected in 36% of in situ melanoma cases
and in 18% of superficial melanoma cases, while in highly invasive melanoma, HA staining inten-
sity was mainly weak in tumor cells. However, the tumor stroma was highly HA positive in all groups,
while CD44 staining intensity and coverage were reduced in tumor stroma compared to benign
nevi. HYAL1 immunoreactivity was found in melanocytic cells both in benign nevi and melanoma
samples while the tumor stromal cells were negative. HYAL2 staining was increased in the melanoma
cells and the stroma, suggesting that the increased expression of HYAL2 is responsible for the HA
clearance during the invasive growth of melanoma. The results from HA and HYAL2 stainings will
be compared with the clinical follow-up data to study the prognostic value of HA and HYAL2 in
melanoma.
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Differential expression of Vimentin, Nestin and Plectin in melanoma
F Ino,1 G Kaya,1 V Piguet2 and L Fontao1 1 Dermatology and Laboratory Medicine, University
Hospital of Geneva, Geneva, Switzerland and 2 Dermatology and Wound Healing, University
Hospital of Wales, Cardiff, United Kingdom
Microtubules and actin filaments, two elements of the cytoskeleton that play important roles in mito-
sis, cell signaling and motility have been successfully targeted to treat cancers. The contribution of
the Intermediate Filaments (IF), the third element of the cytoskeleton and of its associated proteins,
such as plectin has so far received little attention in cancer. Here we have evaluated the expression
of plectin isoforms and of two IF proteins, vimentin and nestin in melanomas and in cells derived
from giant congenital nevi, primary melanomas and metastatic melanomas. We showed coexpres-
sion of plectin and vimentin in S100+/Melan-A+ cells found in normal skin as well as in dysplas-
tic nevi and melanomas. Nestin is not detected in normal melanocytes and weakly expressed in
dysplastic nevi. Nestin is strongly expressed with plectin and vimentin in melanomas. Next we have
assessed the expression of plectin, vimentin and nestin in various cells lines; Mewo (metastatic
melanoma); T921A and Me300 (primary melanomas); NCG041 (giant congenital melanocytic nevi).
We showed that plectin and vimentin are expressed by all cell lines. In contrast nestin is expressed
by MeWo and T921A cells and to a lesser extent by NCG041 cells, but is not detected in Me300
cells. We found that plectin is associated with IF made of vimentin in NCG041 and Me300 cells
whereas it is bound to IF containing vimentin and nestin in T921A and Mewo. RT-PCR analysis
showed that some plectin isoforms are differentially expressed by the various cell lines whereas
others are constitutively expressed. Our findings demonstrated that: 1/ vimentin and plectin are co-
expressed by normal melanocytes, whereas abnormal cells are expressing plectin together with
vimentin and nestin 2/ plectin isoforms are differentially regulated in cells isolated from nevi, pri-
mary melanomas and metastatic melanomas. Additional studies are being conducted to determine
whether the same is true in various types of melanoma and could be helpful for melanoma diag-
nosis and/or prognosis.
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Hesperidin, a natural flavonoid, reduces hyperpigmentation in vitro and aging spots in vivo
following oral intake
AG Gueniche,1 D Philippe,2 P Bastien,1 P Sextius,1 D Barron,2 E Buyukpamukcu2 and I Castiel-
Higounenc1 1 Research and innovation, L’Oreal, Clichy, France and 2 Research center, Nestle,
lausanne, Switzerland
Solar lentigo is characterized by an increased production and accumulation of melanin in human
epidermis and an increased prevalence in aging. Aim of this work was to investigate whether hes-
peridin, a natural flavonoid extracted from orange peel was able to modulate UV-induced melano-
genesis in vitro and age-associated lentigo in vivo in women. Co-culture models, as reconstructed
epidermis exposed to UV, were used for the in vitro evaluation of hesperetin-7-O-beta-D-glucuronide,
one of the major human metabolite of hesperidin. In vivo, 66 female volunteers with at least 2 hand
spots (solar lentigo) were randomly supplemented with 500 mg hesperidin (n=33) or with mal-
todextrin (n=33) during 4 months. At day 56 and 112, brightness of aged spots was determined.
Moreover, biological markers (Ki67, collagen IV and VII) were analyzed by immunohistochemistry
on skin biopsies. In vitro, we found that hesperedin metabolite exhibits significant depigmenting
effect due to reduction of melanogenesis. In the human trial, evolution of aged spot brightness sig-
nificantly decreased in the hesperidin group compared to the placebo group from D0 to D56
(p=0.0199) and to D112 (p=0.0086). In addition, hesperidin shows a significant increase of Ki67
and stratifin, markers associated with skin renewal and epidermal metabolism. Finally, staining of
collagen IV and VII, of collagen network, exhibited a normalization of dermo-epidermal junction
(DEJ) and dermal matrix markers for the subjects supplemented with hesperidin compared to the
placebo group. Hesperidin may play a major role in the improvement of melanocyte environment
in vivo. We can assume that by improving dermal and DEJ structures, the oral intake of hesperidin
may also limit the accumulation of excessive pigment deposit and the formation of aging spots. Alto-
gether, these data show that hesperidin is of particular interest in nutritional supplementation to
modulate brown spots associated with skin aging.
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TSPO expression alterations in cutaneous melanoma
A Zubova, M Aksenenko and T Ruksha Pathophysiology, Krasnoyarsk State Medical University,
Krasnoyarsk, Russian Federation
The 18-kDa translocator protein (TSPO) is a primarily mitochondrial protein that participates in
steroid biosynthesis, cell proliferation, differentiation, apoptosis, and the regulation of mitochon-
drial function in general. TSPO has been implicated in carcinogenesis via its ability to facilitate trans-
port cholesterol into mitochondria for increased energy needs of tumor cells. The purpose of this
study was to investigate TSPO involvement in melanoma pathogenesis. Melanoma specimens were
collected from patients with primary melanoma at the Krasnoyarsk State Oncological Dispensary
from 2004 through 2009. The study was approved by the Local Ethics Committee of Krasnoyarsk
State Medical University. Skin biopsies (n=77) were divided into four groups in accordance with
the Clark level of invasion (I-II, III, IV, V). TSPO expression was analyzed by immunohistochemistry
and real-time PCR. TSPO expression was detected in 87.5% of the melanoma skin biopsies. The
TSPO-positive cells were found in tumor nodes and epidermal keratinocytes and also in sweat and
sebaceous gland cells with preferential cytoplasmic localization. No differences in TSPO mRNA
expression levels between normal and melanoma skin were found, and these results could be
explained by the absence of TSPO expression alterations in the epidermis or other dermal compo-
nents, such as endothelial cells and fibroblasts. The number of TSPO-positive melanoma cases
increased with tumor progression irrespective of age or gender of patients. Similar findings were
obtained while examining TSPO expression levels in melanoma cells in relation to the Clark inva-
sion stage of the tumor. Indeed, the immunohistochemical index was elevated in invasive tumors
characterized as Clark level V as compared to those characterized as level I and II. Taken together,
these results suggest a role for TSPO in melanoma growth and progression.
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SOD activity and copper, zinc, manganese status in melanocytic tumors
C Nicolae,1 M Ciortea,2 C Ciortea3 and I Nicolae4 1 Pharmacology, University of Medicine and
Pharmacy, Bucharest, Romania, 2 Internal Medicine, University of Medicine and Pharmacy,
Bucharest, Romania, 3 Nuclear Physics, IFIN-HH, Bucharest, Romania and 4 Dermatological
Research, “Victor Babes” Hospital of Infectious Diseases, Bucharest, Romania
Aim. The study aimed to evaluate a correlation between status of copper (Cu), zinc (Zn), man-
ganese (Mn) and SODs activity, in melanocytic tumors. Material. Method. The study included 108
patients with melanoma (79 primary melanoma- group A, 29 metastatic melanoma – group B), 49
with precancerous lesions (group C) and 40 healthy individuals (group D). Biological parameters.
SODs activity was measured by spectrophotometry, Cu, Zn and Mn status by positron induced X-
ray emission method at TANDEM accelerator in IFIN-HH. MnSOD was differentiated from Cu Zn
SOD by resistance to potassium cyanide. Results. Cu, Zn, Mn concentration and SODs activity were
compared with those in group D. Ratios obtained were: for Mn in tumoral tissue 7,64 (nevi versus
skin), 1,16 (melanoma versus skin), 1,10 (metastases versus skin) and in blood: 1,17 (A versus D),
1,88 (B versus D), 1,95 (C versus D); for MnSOD: in skin tumors: 1,17 (nevi versus skin), 0,81
(melanoma versus skin), 0,72 (metastases versus skin) and in blood: 0,94 (A versus D), 0,86 (B ver-
sus D), 0,73 (C versus D), for Zn: in tumoral tissue: 2,31 (nevi versus skin), 1,47 (melanoma versus
skin), 1,39 (metastases versus skin) and in blood: 0,98 (A versus D), 0,86 (B versus D), 0,77 (C ver-
sus D); for Cu: in skin tumors: 0,65 (nevi versus skin), 0,96 (melanoma versus skin), 0,98 (metas-
tases versus skin) and in blood: 1,18 (A versus D), 1,86 (B versus D), 2,07 (C versus D); for Cu Zn
SOD: in tumoral tissue: 0,98 (nevi versus skin), 0,87 (melanoma versus skin), 0,88 (metastases ver-
sus skin) and in blood: 0,99 (A versus D), 0,73 (B versus D), 0,69 (C versus D). No significant cor-
relations were obtained between Cu, Mn, Zn status and SODs activities. Conclusions. In patients
with malignant melanoma low levels of Cu Zn SOD and Mn SOD were expressed, comparing with
normal tissue; SODs activity decreased and this might increase vulnerability to oxidative stress.
753
Effects of Low-dose Heavy Ions on the Embryonic Development of Melanoblasts and
Melanocytes in the Epidermis and Hair Bulb of Mice
T Hirobe, K Eguchi-Kasai, K Sugaya and M Murakami National Institute of Radiological
Sciences, Chiba, Japan
Effects of prenatal low-dose irradiations of heavy ions on the embryonic development of melanocytes
have not been well studied. The aim of this study is to investigate in detail the effects of low-dose
heavy ions on the development of melanocytes in embryonic skin of mice. Pregnant females of
C57BL/10J mice were irradiated whole-body at 9 days of gestation with a single acute dose of sili-
con, argon and iron ions in addition to gamma-rays, and the number of melanoblasts and melanocytes
in the epidermis and hair bulbs of 18-day-old embryos was counted histochemically. Drastic decrease
in the number of epidermal melanoblasts and melanocytes and hair bulb melanocytes was observed
even in 0.1 Gy-treated embryos, and the number gradually decreased as dose increased. The decrease
in the number of dorsal hair bulb melanocytes well correlated with the linear energy transfer of radi-
ations tested, but not in the number of dorsal and ventral epidermal melanoblasts and melanocytes
as well as ventral hair bulb melanocytes. Moreover, the effects of heavy ions on the ventral skin
were greater than those on the dorsal skin especially in melanocyte numbers. These results suggest
that the prenatal exposure to low-dose heavy ions possesses an inhibitory effect on the prolifera-
tion and differentiation of melanocytes with a greater effect on the ventral skin than on the dorsal
skin.
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Measurement of eumelanin and pheomelanin of skin phototpyes I-VI obtained using a non-
invasive inverse spectroscopy analysis
AM Hani,1 H Nugroho,1 R Jolivot2 and F Marzani2 1 Centre for Intelligent Signal and Imaging
Research, Universiti Teknologi PETRONAS, Tronoh, Malaysia and 2 Laboratorie Le2i,
University of Burgundy, Dijon, France
The Fitzpatrick skin type is used to assess pigmentation and as a predictor for the risk of develop-
ing skin cancer. The assessment is subjective and is prone to error due to respondent bias. The aim
of the study is to quantify the melanin types (eumelanin and pheomelanin) and their relative con-
centrations of skin types I-VI non-invasively. An objective assessment of normal subjects will pro-
vide a baseline data in monitoring skin response to sunlight. A study was conducted in Malaysia
and France involving 110 participants (I=14; II=17; III=20; IV=19; V=23; VI=14). The spectral
reflectances (340 nm -740 nm) of the participants’ forearms are measured using a spectrophotometer
and analysed by an inverse spectroscopy analysis. The method derives optical properties of skin by
fitting the reflectance obtained from modelling light interactions with skin layers and choromophores
to the actual reflectance obtained from spectrophotometer. It was found that the relative mean con-
centrations (g/l) of eumelanin increases (I= 21.99 ± 11.3, II=29.54 ± 22.3, III = 32.62 ± 14.4, IV =
38.2 ± 22.0, V= 51.56 ± 24.5, VI = 57.26 ± 29.6) from white to dark skins. On the other hand,
pheomelanin decreases (I= 2.17 ± 1.4, II= 2.06 ± 0.9, III = 2.04 ± 1.1, IV = 2.02 ± 0.8, V= 2.01 ±
1.2, VI = 1.88 ± 1.2). The volume fraction of melanosomes was found to increase (I= 0.04 ± 0.022,
II=0.07 ± 0.05, III = 0.154 ± 0.04, IV = 0.178 ± 0.07, V= 0.29 ± 0.07, VI = 0.35 ± 0.07) as expected.
These values estimated are in good agreement with those reported by Jacques (Surg Clin North Am,
1992). The ratio between pheomelanin and eumelanin of type IV was 0.05, which is close to the
value of 0.049 as reported by Parsad (Br J Dermatol, 2003) who uses biochemical analysis. These
findings indicate that the inverse spectroscopy analysis is potentially useful for non-invasive in-vivo
pigmentation analysis. Further studies are required to determine the accuracy and its reliability in
clinical practice.
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Feasibility of in vivo confocal microscopy in diagnosing nodular lesions
C Longo,1 S Ciardo,2 F Farnetani,2 A Cesinaro,3 G Ponti2 and G Pellacani2 1 Dermatology Skin
cancer unit, Reggio emilia, Italy, 2 Department of Dermatology university of Modena and
Reggio Emilia, Modena, Italy and 3 Department of Pathology, Modena, Italy
Nodular lesions represent a clinical and dermoscopic challenges for Clinicians since nodular
melanoma can mimic any melanocytic and non-melanocytic tumors. In the modern era, confocal
microscopy has emerged as promising tool that allows a rapid and noninvasive visualization of the
skin at a cellular level. The major limitation of this technique relies in the limited depth penetration
that explores up to the papillary dermis (200 microns). The aim of our study was the evaluation of
histopathologically proven nodular lesions excised at two distinct referral centers that were imaged
by means of in vivo confocal microscopy. Confocal criteria for distinct categories (melanoma, nevi,
basal cell carcinomas, epithelial tumors) were blinded evaluated by an expert Confocalist. A total
of 140 lesions were included in our study. Confocal microscopy provided a correct diagnosis in
114 cases out of 140; more specifically, all basal cell carcinomas but one were correctly diag-
nosed. 21 out of 23 melanomas were correctly diagnosed by confocal microscopy; the remaining
two melanomas showed extensive areas of ulceration that hampered the confocal imaging. Among
the lesions where confocal microscopy did not achieve a correct diagnosis, we found dermatofi-
bromas and metastasis characterized by a deep dermal proliferation. In conclusion, confocal
microscopy represents a useful adjunct in clinical management of nodular lesions for which a cor-
rect diagnosis can be obtained for the majority of cases.
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Effect Of Licorice Extract-Contained Cosmetic Ingredient On Melanogenesis And Molecular
Mechanism Study
M Goh, Y Na, H Lee and J Cho Skin Research Institute, Amorepacific R&D center, Yongin,
Republic of Korea
It is well known that extract of Licorice species has saponins, flavonoids, isoflavones, coumarins,
and stilbenoids, and used as an effective disease treatment including peptic ulcer, cough, consti-
pation, and other diseases. Dermatologically, Licorice extract is famous ingredient for skin whiten-
ing in East-Asian countries. In this study, we investigated the inhibitory effect of licorice extract on
melanogenesis in various assay systems which are stimulated with melanogenic agents including
α-MSH, Endothelin-1 and/or UVB, and figured out the molecular mechanism of depigmentation
effect. Licorice extract inhibited melanin synthesis in tobacco extract-stimulated melan-a, mouse
melanocytes. Also, Licorice extract inhibited pigmentation in α-MSH stimulated mouse
melanocytes/keratinocytes (melan-a/SP-1) co-culture system. Even in UVB/Endothelin-1 treated
Asian melanocyte-contained human skin-equivalents (MelanoDerm, MEL-300-A), Licorice extract
treatment showed decrease of pigmentation as effective as kojic acid. We further investigated the
mechanism of Licorice extract on melanogenesis. Licorice extract directly inhibited mushroom tyrosi-
nase activity in a dose-dependent manner (IC50=60ppm). Moreover, the real-time PCR revealed
that Licorice extract caused dose-dependent down-regulation of melanogenic genes mRNA includ-
ing microphthalmia-associated transcription factor (MITF), tyrosinase, tyrosinase-related protein 1,
and dopachrome tautomerase in melan-a cells. In highest dose Licorice extract treated group, MITF
gene expression was reduced to half of untreated control group. In this study, we first found that
Licorice extract affected transcriptional down-regulation of melanogenic gene expressions as well
as tyrosinase activity inhibition. Further studies are needed to identify the precise regulatory path-
ways.
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DAV-feron chemotherapy reduces circulating tumor cells and restores Th17 cells in melanoma
H Fueki-Yoshioka, R Hino and M Nakamura Dermatology, University of Occupational and
Environmental Health, Kitakyushu, Japan
A postoperative adjuvant chemotherapy regimen: dacarbazine, nimustine hydrochloride and vin-
cristine sulfate with interferon-beta (DAV-feron) is widely used for melanoma patients in Japan.
Recent studies have suggested that Th17 cells may play significant roles in modulating tumor microen-
vironments, and circulating tumor cells exist in advanced melanoma patients. However, the effect
of DAV-feron on circulating Th17 cells and circulating tumor cells has not been well understood
yet. Therefore, we examined peripheral blood cells of 28 melanoma patients before and after the
DAV-feron therapy. The peripheral mononuclear cells were stimulated by phorbol 12-myristate 13-
acetate and ionomycin, and stained for surface CD3 or CD8 and intracytoplasmic IL-17. The ratio
of Th17 cells had a tendency to decrease with progressing T classification. After 1 cycle of DAV-
feron chemotherapy, the percentage of Th17 cells in peripheral blood was significantly increased.
At the same time, we examined the ratio of TGF-β and IFN-γ expressing T lymphocytes by intracy-
toplasmic stainings. Although the percentage of TGF-β and IFN-γ positive cells had a tendency to
increase with the development of T classification, the percentage of IFN-γ positive cells in the patients
with metastatic melanoma was lower than non-metastatic patients and normal controls. Moreover,
we investigated the number of melanoma-associated sulfate proteoglycan (MCSP) positive cells from
peripheral blood, which can be considered as circulating tumor cells in advanced melanoma patients.
The number of MCSP positive cells in peripheral blood of patients with metastatic melanoma was
significantly higher than the patients without metastasis. After the DAV-feron chemotherapy, the
number of MCSP positive cells was significantly reduced. These findings indicated that patients with
metastatic melanoma were in immunosuppressed condition, but DAV-feron therapy modulated
immunoreaction and reduced circulating tumor cells in the patients with melanoma.
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Plasma Neuropeptide Y In Patients With Melanoma
Y Gilaberte,1 J Puzo,2 R Lastra del Prado,3 M Ferrer,2 S García,2 M Puzo,2 A Juarranz,4 J Vera5 and
I Alvarez-Busto3 1 Dermatology, Hospital San Jorge, Huesca, Spain, 2 Biochemistry, Hospital
San Jorge, Huesca, Spain, 3 Oncology, Hospital San Jorge, Huesca, Spain, 4 Biology, Faculty
of Sciences, Autonoma University, Madrid, Spain and 5 Pathology, Hospital San Jorge,
Huesca, Spain
Neuropeptide Y (NPY) is widely found in the nervous system and has a role in numerous physio-
logic processes. In addition, NPY has been found in different malignancies. We have recently pub-
lished that NPY is significantly expressed in biopsies of cutaneous melanomas, especially the
nodular type, being associated with invasiveness. The aim of the study was to compare plasma NPY
concentration of patients diagnosed with cutaneous melanoma versus controls. Observational study
in patients diagnosed with cutaneous melanoma attended in San Jorge Hospital, Huesca, Spain,
from December 2010 to June 2011. A control population was taken from blood donors in the same
hospital. NPY was determined using EIA (Phoenix, Europe, GMBH, Karlsruhe, Germany). Clinical
and histological variables of melanoma were also evaluated. 54 patients and 35 controls were ini-
tially included in the study but only 34 cases and 15 controls were considered valid to analyse.
40,1% of the patients and 66,7% of the controls were men. Mean age was 52.67+17.85 years old
for patients and 44.31+11.37 for controls. Plasma concentration of NPY were not significant dif-
ferent in patients and controls. Among the group of melanomas, superficial spreading melanomas
presented the highest levels of NPY (8.2+14.26 ng/ml) followed by nodular melanomas (2.06+2,34
ng/ml) (p=0.879). Those patients with metastases presented higher levels than those without them
(7.01+9.72ng/ml and 2.58+3.95 ng/ml respectively (p=0,336). NPY plasma concentrations in patients
with melanoma seem to be correlated to the stage of disease. However, our sample of metastatic
melanomas was small and our differences don’t reach statistical significance. More studies are in
progress in order to increase the sample to confirm these preliminary results.
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Morphological characterization of Solar Lentigines by in vivo Reflectance Confocal Microscopy:
a longitudinal approach
C Pollefliet,1 H Corstjens,1 D Yarosh2 and L Declercq1 1 Estée Lauder Companies, Oevel,
Belgium and 2 Estée Lauder Companies, Melville, NY
Solar lentigines or age spots are benign flat brown macules of the skin that appear mostly on the
dorsum of hands, face and forearms. Their development is accelerated by UV exposure. Little is
known about the mechanisms responsible for the formation and development of solar lentigines.
Previous investigations on solar lentigines using confocal microscopy revealed a profound struc-
tural deformation of the dermal papillae and an increase in the number of dermal papillae. A clin-
ical study was designed in which a total of 19 age spots were followed over a 5 years time period.
Analysis of dermoscopic pictures showed a statistically significant increase over time in color con-
trast (p=0.002) between the solar lentigo and the surrounding skin. The increase in contrast was fur-
ther confirmed to be associated with a progressive darkening of the solar lentigo (p<10-3). In addi-
tion there was a statistically significant increase of the lesion size (p<10-4). Evaluation by confocal
microscopy revealed a progressive deformation (p=0.03), expressed as a reduction of the circular-
ity index of the dermal papillae, and increase in the number of dermal papillae (p=0.047). From
these data it is concluded that RCM is a useful non-invasive clinical tool for the characterisation of
solar lentigines, and in particular the compressive deformation of the dermal papillae. This defor-
mation aggravated over a time period of five years. To the best of our knowledge, this is the first time
that the in vivo time dependent progression of solar lentigines was supported by RCM images, con-
tributing to an improved understanding of the formation and progression of solar lentigines.
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Ultraviolet A radiation increases invasiveness of melanoma cells
A von Thaler, Y Kamenisch, W Schuller, M Röcken, F Meier and M Berneburg Department of
Dermatology, Eberhard Karls University, Tuebingen, Germany
Melanoma is a malignant skin tumor deriving from melanocytes, characterised by high morbidity
and mortality. While recent studies elegantly demonstrated a causative role for a single high dose
of ultraviolet (UV)B (280-320nm) radiation in the development of melanoma, the role of UVA (320-
400nm) in the pathogenesis of human melanoma remains unclear. We could previously show, that
repetitive exposure of melanoma cell lines to UVA irradiation increases lactate levels and increases
levels of the transketolase-like-1 enzyme, which is an important enzyme of the pentose phosphate
pathway. These findings reason for an increase of aerobic glycolysis after repetitive UVA exposure.
This phenomenon is characteristic for many carcinomas and is known as the Warburg effect. To gain
more insight in the role of UVA in the pathogenesis of melanoma it is important to focus investiga-
tions on invasiveness, which is important for aggressive melanomas. Melanoma cells of different
malignancies with and without sublethal, repetitive UVA irradiation were investigated for their inva-
siveness with Boyden chambers. After repetitive UVA irradiation the level of invasive cells increased.
Also additional lactate increases the invasiveness. This points to an increased invasiveness of
melanoma cells after the lactate produced via the Warburg effect.
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Real life experience with pegylated interferon vs conventional interferon treatment in
melanoma patients
S Rozati, L Naef and R Dummer Dermatology, University Hospital Zurich, Zurich, Switzerland
Interferon alpha is approved as adjuvant therapy for melanoma patients, but it is associated with an
extensive range of side effects. We evaluated pegylated interferon and low-dose conventional inter-
feron treatment in melanoma patients to identify the most common adverse events as well as rea-
sons to cease treatment. From 99 melanoma patients treated with interferon at our center, 50 were
treated with interferon-alpha; 48 with pegylated interferon and one lacked sufficient data. Overall,
73% of patients reported adverse events. The main reason to stop interferon treatment was the occur-
rence of adverse events, followed by disease progression and regular completion of therapy. A dose
reduction due to side effects was necessary significantly more often in the pegylated interferon group.
Patients treated with pegylated interferon had a significantly higher tendency to develop neutrope-
nia (37.5% vs. 10.9%, p=0.004). There was no significant difference in overall survival, as expected.
Here we compared the two interferon forms outside clinical trials. While the use of pegylated inter-
feron is certainly more convenient for the patient in terms of application, its increasing use is demand-
ing close monitoring and early medical interventions to avoid treatment discontinuation. In this
study, side effects tend to occur more often and lead to significantly more discontinuation of ther-
apy or dose reductions in patients treated with pegylated interferon. Despite the higher number of
neutropenic patients in the pegylated group, no infections were reported. Therefore, in an asymp-
tomatic patient, close follow ups during the neutropenic episodes might be sufficient. Further
investigation will shed light on the differences in response between the two forms, the degree of
side effects and maybe which subpopulation of melanoma patients will benefit from which form.
At this point, selection of patients for each form/ dose of interferon treatment might be best done at
an individual level depending on the responsible physician, patient’s tolerability, cost and other cir-
cumstances affecting decision making.
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Computerised vitiligo treatment analysis of paediatric cases obtained from digital photogra-
phy correlates with dermatologist assessment
AM Hani,1 H Nugroho,1 N Shamsudin,2 SA Kader and S Hussein3 1 Centre for Intelligent Signal
and Imaging Research, Universiti Teknologi PETRONAS, Tronoh, Malaysia, 2 Dept of
Medicine, University Putra Malaysia, Selangor, Malaysia and 3 Dept of Dermatology,
Damansara Specialist Hospital, Selangor, Malaysia
Vitiligo is an acquired, idiopathic pigmentary disorder characterized by depigmented macules and
patches that result from loss of epidermal melanocytes. Currently there is a lack of an objective
measurement system to evaluate and quantify therapeutic response of vitiligo treatment accurately.
In our previous study, the use of imaging and computerised method has been explored and devel-
oped for this purpose. The aim of this study is to evaluate and compare the assessment of the com-
puterised method and dermatologists. Fifteen (15) paediatrics patients were enrolled in the study.
The patients were asked to apply tacrolimus ointment 0.03% twice daily for 24 weeks. Scheduled
treatment visits were conducted once every six weeks. Digital photographs (RGB images) were taken
at each visit. The images were analysed using a combination of Principal Component Analysis and
Independent Component Analysis. Using the computerised method, 4(27%) patients achieved
mild overall repigmentation, 2(13%) moderate and 3(20%) had excellent overall repigmentation
with mean repigmentation (MPR) greater than 75%, 3(20%) had no response and 3(20%) had
worsening of the disease. With the Physician’s Global Assessment, it was found that 4(27%) patients
had mild response, 4(27%) had moderate and 2 (14%) achieved at least 50% repigmentation.
None of the children’s vitiligo was observed to have worsened with treatment in contrast to the com-
puterised method. Further analysis concluded that the 2 patients, whom the computerised method
analysed as worsening, had increasing size of vitiligo patches during the study period indicating
high sensitivity of the computerised method. The Kappa test of consistency value between both
assessments was 0.64 which shows substantial agreement between the two observations.
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Interactions of a prunus domestica extract with melanocytes – keratinocytes in vitro:  A gly-
cobiological process
E Prud’Homme,1 BA Bernard,2 G Sore,1 V Jehan1 and J Laboureau1 1 L’Oréal Research and
Innovation, Chevilly-Larue, France and 2 L’Oréal Research and Innovation, Clichy, France
It is accepted that melanosomes are transferred from melanocytes to keratinocytes through a phago-
cytosis mechanism. In a previous experiment using keratinocyte-melanocyte co-culture, it was shown
that Prunus domestica extract could down-regulate the melanosome transfer thereby inhibiting
melanosome phagocytosis by the keratinocyte. The present study aimed at defining the mechanism
whereby Prunus domestica can exert this controlling effect on phagocytosis process. It was hypoth-
esized that such property could be linked to a competition process through glycans since the extract
is rich in mono or oligosaccharides. Glycan profiling was analyzed through monitoring interac-
tions with lectins. CFSE (Carboxyfluorescein succinimidyl ester)-labelled cells were incubated on
lectin arrays. After washing, fluorescence was recorded. Lectin profiling was analyzed by monitor-
ing interactions with neoglycoproteins. Cells were incubated with fluoresceinylated neoglycopro-
teins. After washing, fluorescence was recorded and corrected according to intrinsic fluorescence
of each neoglycoprotein. Our results demonstrate specific interactions of Prunus domestica extract
with each epidermal cell type, more precisely keratinocytes and melanocytes. With regard to ker-
atinocytes, the extract does not contain glycans able to inhibit lectin interaction with keratinocyte
surface. Inversely, the extract contains saccharide units able to inhibit the binding of βGlc-BSA
neoglycoprotein to osidic receptors. As for melanocytes, the extract contains glycans able to inhibit
lectin binding to melanocyte surface and thus potentially able to inhibit glycan interactions of
melanosomes with lectin type receptors on keratinocyte recipient cell. Conclusions: Taken alto-
gether this data suggests that mono or oligosaccharides contained in the Prunus domestica extract
are potentially able to decrease melanosome interactions with keratinocytes through inhibiting gly-
can binding to osidic receptors.
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Vitiligo-like-depigmentation in metastatic melanoma patients upon immunotherapy: A sys-
tematic review
H Teulings,1 J Limpens,2 SN Jansen,1 JB Reitsma,3 PI Spuls1 and R Luiten1 1 Dermatology,
Academic Medical Center, Amsterdam, Netherlands, 2 Medical Library and Dutch Cochrane
Center, Academic Medical Center, Amsterdam, Netherlands and 3 Biostatistics, Academic
Medical Center, Amsterdam, Netherlands
Vitiligo-like depigmentation can occur in melanoma patients, both spontaneously and after
immunotherapy treatment. Auto-immunity and vitiligo development in melanoma patients treated
with systemic immunotherapy has been suggested to favor clinical outcome. The induced depig-
mentation results from strong anti-melanoma immunity that also targets healthy melanocytes and
might therefore be a useful as a visible clinical parameter of anti-tumor immunity. To evaluate this,
an overview of the frequency and prognostic value of vitiligo-like depigmentation in melanoma
patients is needed. We aim at providing a comprehensive overview of vitiligo development in metasta-
tic melanoma patients treated with immunotherapy. We performed an exhaustive search of the elec-
tronic databases MEDLINE and EMBASE (OVID) from January 1st 1995 to April 27th 2012. We first
searched for studies on vitiligo-like depigmentation (including vitiligo and synonyms) and melanoma.
To find trials that scored vitiligo without mentioning it in the abstract, we next searched for all
melanoma trials and observational studies using specific immunotherapeutic interventions. After
deduplication the search identified a total of 3244 references. All types of immunotherapy studies
performed in stage III-IV melanoma patients reporting on clinical response and comprising a toxi-
city evaluation with auto-immunity screening were included for analysis. All data were independ-
ently extracted by 2 reviewers. We categorised the 150 included studies, of which 119 studies
reported vitiligo, into subgroups regarding immunotherapy type and assessed vitiligo frequency per
group. Vitiligo-like depigmentation was often described in the included studies. The frequency var-
ied per immunotherapeutic strategy, it mostly occurred upon adoptive cell transfer therapy. With
these data the prognostic value of vitiligo regarding clinical outcome and survival will be further
investigated.
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Blue-black rule: identification of histologic substrate by means of in vivo confocal microscopy
F Farnetani,2 C Longo,1 G Argenziano,1 I Zalaudek1 and G Pellacani2 1 Dermatology Skin can-
cer unit, Reggio emilia, Italy and 2 Departement of Dermatology university of Modena and
Reggio Emilia, Modena, Italy
Nodular melanoma is the most aggressive melanoma subtype. The egf rule referring to the clinical
appearance of the lesion (e=elevated and f=firm) and to the fast growth (g) rate is coupled with the
dermoscopic analysis to obtain a correct diagnosis. However, standard dermoscopic criteria that
are usually seen in superficial spreading melanoma may not be present in nm that is mainly char-
acterized by a predominant dermal component and a limited or absent epidermal involvement.
Recently, has been identified a new dermoscopic criterion named blue-black rule. This term refers
to the combination of blue and black colors in pigmented nodular lesions, involving at least 10%
of the lesion surface. However, the histopathologic substrate of the b-b rule was not investigated.
In vivo confocal microscopy is a modern imaging tool that scan the skin horizontally while obtain-
ing high resolution images with a nearly histologic resolution. The horizontal scanning of confocal
microscope offers the possibility to obtain a side-by-side comparison with the corresponding der-
moscopic images . The aim of our study is to elucidate the morphologic substrate of the b-b rule by
means of in vivo confocal microscopy and to correlate the confocal findings with the histopatho-
logic aspects. A total of 27 cases were included (melanoma and metastasis), retrospectively evalu-
ated for the presence of bb rule and a side by side comparison between confocal mosaics and
histopathologic sections was performed. Histopathologic features included the presence of ulcera-
tion, thinning of the epidermis, consumption of epidermis, pagetoid spread presence of inflamma-
tory infiltrate. Our data confirmed that the presence of blue color is correlated with the presence
of solid dermal proliferation either sheets of cells or nesting pattern. Concerning the black colour,
it results correlated not only to the epidermal involvement but also to the different depth of the pig-
ment contained in neoplastic cells.
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Melaleuca alternifolia - derived terpenes for the tailored treatment of superficial and deep
skin cancers
CM Bertram,1 DJ Ireland,1 SJ Greay,1 TV Riley2 and MW Beilharz1 1 Pathology and Laboratory
Medicine, University of Western Australia, Crawley, WA, Australia and 2 Microbiology and
Infectious Diseases, PathWest Laboratory Medicine, Nedlands, WA, Australia
Non-melanoma skin cancers (NMSC) are the most common type of skin cancers and their surgical
treatment is a significant burden for patients and the health care system. The use of secondary plant
metabolites as local chemotherapy agents for skin cancers has recently won significant support. Tea
tree oil (TTO) from the Australian native Melaleuca alternifolia contains >100 different terpenes
and possesses anticancer properties. We tested our established murine subcutaneous NMSC (LK-
2), melanoma (B16) and mesothelioma (AE17, AB1) tumour models that all show tumour regres-
sion or growth inhibition when applying >10% TTO in di-methyl-sulfoxide (DMSO) topically. Elec-
tron microscopy and flow cytometry was performed to assess the cellular changes of tumour cells
and the involvement of immune cells in tumour clearance after TTO treatment in vivo. Results
show that TTO induces cancer cell necrosis as terpenes integrate into cell membranes causing their
destabilisation. Skin penetration studies using Franz diffusion cells and mouse skin were conducted
and penetrating TTO/DMSO components were measured using gas chromatography-mass spec-
trometry. Of the TTO, only terpinen-4-ol, α-terpineole and 1,8-cineole can be measured in and
under the skin, suggesting that the observed anticancer effect is mainly mediated these terpenes.
Recently, we have modulated major terpene concentrations, penetration enhancers and drug deliv-
ery to the tumour and increased anti-tumour efficacy. This study contributes to the development of
tailored terpene formulation for a more effective treatment of superficial and deep skin cancers.
This pre-clinical data is pivotal for the translation into the clinic in the near future.
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Dermoscopy in Multiple Primary Melanomas: a multicenter, retrospective, observational study
E Moscarella,2 I Zalaudek,3 H Rabinovitz,5 S Puig4 and G Argenziano1 1 Dermatology and Skin
Cancer Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 2 Dermatology, University
of Modena and Reggio Emilia, Modena, Italy, 3 Dermatology, University of Graz, Graz,
Austria, 4 Melanoma Unit, Hospital Clinic, Barcelona, Spain and 5 Skin Carcer Plantation,
Private, Barcelona, Spain
Patients diagnosed as having melanoma are at increased risk of developing additional primary
melanomas. A number of tumor registry and population-based studies have demonstrated that the
risk for developing an additional primary melanoma ranges from 1.3% to 8.0% in large retrospec-
tive reviews. Furthermore, it has been demonstrated that the second primary lesions that occur are
significantly thinner than the index lesion, probably as a result of increased surveillance of these
patients. These findings corroborate the necessity to extend life long the follow-up surveillance of
patients with melanoma. Dermoscopy is nowadays a pivotal tool in the diagnosis of skin tumors.
Most recent melanoma guidelines strongly advocate the use of dermoscopy for skin cancer screen-
ing and surveillance.A series of studies have investigated epidemiological, clinical and genetic char-
acteristics of MPM patients. However, only two studies have examined the clinical phenotype and
dermoscopic features of these melanomas, both reporting on single patients who had presented with
multiple synchronous melanomas, showing opposite results.The first study reported on a patient
who had presented 3 dermoscopically different melanomas. On the contrary, the other case had
presented 3 dermoscopically similar lesions. Knowing that in patients with MPM each subsequent
lesion looks similar to the previous lesion or different, might help clinicians in earlier recognition
of the eventual subsequent melanoma. The aim of our study was to evaluate if there is a similar der-
moscopic pattern in a given patient with multiple primary lesions. We conducted a multi-centric,
observational study, and examined the dermoscopic patterns of the index and subsequent melanoma
in a series of 73 patients displaying a total of 160 melanomas.
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Comparison between Trichloroacetic acid and Glycolic acid peels in the treatment of melasma
and post-inflammatory hyperpigmentation in ethnic patients
A Kotb and M Abdel-Hamid Dermatology, National research center, Cairo, Egypt
Introduction & Objectives: Trichloroacetic acid (TCA) & Glycolic acid (GA) peels are well known
for their cosmetic use in the field of dermatology for the treatment of various problems. This group
of chemicals is best known for its degreasing & peeling power. GA peels removes the upper layers
of dead & damaged skin & encourges skin cell regeneration. While TCA forms a frosting reaction
which turns after few hours to a crust with the removal of the upper layer of the skin & inducing
regeneration from the skin adenexa. These two kinds of peels can be used in treatment of fine wrin-
kles, acne vulgaris, melasma, chronic dry skin & uneven pigmentation. Material & Methods: This
study included 20 middle aged female patients complaining of melasma & uneven facial pigmen-
tation & prepared by topical retinoids for 4-6 weeks prior to sessions. GA 70% & TCA 35% were
used. The peeling sessions were Four sessions & they were applied once every 3-4 weeks. The female
patients were divided into 2 groups. GA 70 % was used with the first group. TCA 35 % was used
in the second group. The patients were photographed before & after every session. The results were
evaluated clinically. Results: The first group showed amazing results after two sessions & after the
fourth session most of the patients were satisfied. only one patient from the first group had a rebound
hyperpigmentation & she gave a history of not using the sunscreen properly as prescribed. the sec-
ond group showed satisfactory results after the fourth session. one patient was not satisfied by the
results & we used the GA 70% peel after the fourth session. Conclusions: GA peels are the best rec-
ommended kind of peels for the ethnic group of patients. Good preparation should be done prior
to the peeling procedure. Rebound hyperpigmentation is one of the most distressing adverse effects
& it can be avoided by using the sunscreen creams as precribed (once every two hours). The GA
70% is superior to the TCA 35% in achieving fast results.
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Efficacy of dermatoscopy in the diagnosis of pigmented skin lesions as compared to histopathol-
ogy
M Goldust Student Research committee, Tabriz university of medical sciences, Tabriz, Islamic
Republic of Iran
Introduction: Dermatoscopy can be applied to diagnose pigmented skin lesions considering groups
of simple diagnostic criteria. It can also be used in follow-up schedules in suspicious cases of
melanoma or other non-melanocytic skin malignancies (BCC, seborrheic keratosis, etc). Methods:
67 patients diagnosed as Basal cell carcinoma (BCC) or melanocytic nevus, were evaluated in an
analytical-descriptive study. During one year from May 2009 to April 2010, patients’ lesions were
evaluated with dermatoscopy and results were compared with pathological diagnosis of biopsied
samples. Results: In the present study, patients’ average age was 49.5 ± 18.9 ranging from 24 to 82.
25 patients were male (41%) and 36 (59%) were female. 27 cases (44.2%) were diagnosed with
melanocytic naevi, 28 (45.9%) with BCC and 6 (9.8%) were considered as mixed type. There was
significant correlation between sex and dermatoscopic diagnosis (P= 0.0001). Conclusion: This study
showed that dermatoscopy can be helpful in improving clinical diagnosis while guiding missed
malignant lesions to pathologic evaluations even being useful in evaluating further suspicious or
recurrent cases.
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